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Abstract 
The effect of Galectin-3 in Experimental Uraemia 
Gal-3 is a glycoside binding protein elevated in inflammatory and fibrotic disease 
and highly expressed on cells of a monocyte/macrophage lineage. Elevated 
leucocyte Gal-3 expression encourages leucocyte-endothelial attachment and 
tissue transmigration.  We demonstrate for the first time plasma soluble and 
monocyte Gal-3 is elevated in an experimental model of adenine induced 
uraemia and renal interstitial fibrosis. Galectin-3 knockout mice demonstrate an 
ameliorated adenine diet phenotype with less weight loss, lower serum 
creatinine and less severe renal tubular interstitial injury. This ameliorated 
phenotype is independent of numbers of infiltrating renal interstitial 
macrophages. Extra-renal leucocyte-endothelial transmigration in the 
cremasteric microvasculature visualised by intravital microscopy is not reduced 
in Galectin-3 knockout mice with adenine induced uraemia. The less severe 
disease phenotype of adenine induced uraemia in Galectin-3 knockout mice is 
therefore independent of effects on leucocyte-endothelial interactions. We 
show circulating monocyte subset phenotypic change and renal macrophage 
differentiation in adenine induced uraemia is altered in Galectin-3 knockout mice 
with reduced monocyte Ly6C expression and elevated renal macrophage 
markers of alternative (M2) differentiation. We conclude that Galectin-3 does 
play a role in chronic kidney disease and the development of renal fibrosis by 
influencing monocyte and macrophage differentiation towards an inflammatory 
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phenotype. Strategies to reduce monocyte and macrophage Galectin-3 may 
benefit progressive renal fibrosis in chronic kidney disease. 
16 
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Introduction 
1.1 The Galectin Family 
1.1.1 Lectins 
Lectins are widely conserved proteins that recognise and bind carbohydrate 
sequences on glycolipids and glycoproteins.[1-3] They are present in vertebrates, 
invertebrates, plants and protists (sponge and fungus) suggesting carbohydrate-
lectin interactions in living organisms are important.[4, 5] The binding of some 
lectins to carbohydrate sequences can be as specific as antibody-antigen 
binding.[6] Carbohydrate sequences bound by lectins include the large amount of 
oligosaccharide glycoproteins and glycolipids on extracellular cell membranes 
and also circulating glycans including monosaccharides.[7] A small amino acid 
sequence on animal lectins termed the carbohydrate recognition domain (CRD) 
facilitates carbohydrate-lectin binding.[5] The CRD frequently commonly binds 
the terminal, non-reducing carbohydrate sequence of glycoprotein and 
glycolipids.[2] Lectins can be divided into groups based on CRD amino acid 
sequences.[5] The requirement of calcium to facilitate CRD binding to 
carbohydrate sequence is used to discriminate between the two main lectin 
groups C-type lectins (calcium dependent binding) and S-type lectins (calcium 
independent binding).[5] The C-type lectins include selectins, collectins and 
endocytic lectins, S-type lectins consist of galectins.[1, 5, 8, 9]  
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1.1.2 Galectins 
 Galectins are lectins that specifically bind β-galactosides present on cell surfaces 
and the extracellular matrix.[10] A β-galactoside is a molecule with a galactose 
residue bound to a non-carbohydrate (often a small organic molecule) for 
example lactose.[11]. β-galactosides are present in the glycoproteins, glycolipids 
and proteoglycans distributed over cell surfaces within the glycocalx (a 
glycoprotein-polysaccharide covering the cell membranes of most living cells). [12]  
Intracellular β-galactosides are less frequently occurring and are  limited to 
proteins containing O-linked N-acetylglucosamine.[13] Most galectin binding to 
intracellular ligands is by protein-protein interaction rather than involving the 
CRD. [14] Galectins, by definition, have sequence homology for their CRD- a highly 
conserved canonical amino acid sequence. [15] The first galectin discovered was 
galectin-1 (Gal-1), then known as S-type lectin when identified in 1975 from the 
electric eel. [16] Gal-1 was discovered via its ability to agglutinate red blood cells, 
which was inhibited by the presence of β-galactosides. Further lectins with β-
galactoside binding specificity were discovered independently from sponge, 
nematode and animal tissue.[17] These lectins had similar properties requiring no 
metal ion to facilitate binding (unlike C-type lectins), were water soluble and 
have an acetylated N-terminus. [18] In 1994 the 4 lectins with CRD sequence 
homology for β-galactosides were grouped together and termed galectins.[1] In 
time order of discovery they were termed galectin-1, 2, 3, and 4.[1]  Galectins 
were further subdivided into 3 groups based on the number of CRDs per galectin 
(1 or 2) and whether the CRDs were identical or distinct [Table 1]. [10] Galectins 
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have either 1 or 2 CRDs within a single polypeptide chain. In contrast to C-type 
lectins galectins or S-type lectins the polypeptide chain containing the CRD is not 
attached to a well-defined protein domain. C-type lectins often have several 
CRDs attached to another protein domain.[19] The 3 galectin groups were termed 
prototypical, chimeric and tandem repeat [Table-1]. There are 15 known 
mammalian galectins and 11 of those are present in humans.[20]  
 
 
 
Table 1 : Classification of the Galectin family by carbohydrate recognition 
domain (CRD). There are 3 main groups with the subject of this thesis (Gal-3) 
falling uniquely into its own group. This classification was initially proposed by 
Hirabyashi in 1993 and is still used to distinguish Galectins into both structural 
and functional groups.  
 
  
28 
 
1.1.2.1.1 The Galectin Carbohydrate Recognition Domain 
Membership of the galectin group requires the presence of a conserved CRD 
amino acid sequence; however, this is not enough by itself. Galectins must also 
show affinity for β-galactosides.[11] Some molecules termed ‘galectin like 
proteins’ have the conserved amino acid sequence but do not bind β-
galactosides. [18] Galectin binding to glycoprotein and glycolipids is mediated via 
specific interactions between the galectin CRD and β-galactoside. [15] The galectin 
CRD consists of approximately 135 amino acids folded into a β sandwich 
identified by X-ray crystallography in 1993.[21]  Contained within the CRD is a 
carbohydrate binding site consisting of a 7 amino acid motif termed the 
carbohydrate binding region. The 2 sheets of the β sandwich are curved with a 
convex (5 strands) and concave side (6 strands). Between the 2 sheets are 4 sub 
sites which constitute the carbohydrate binding region.[18]  Carbohydrates attach 
to the concave side which forms a hollow large enough to accommodate a 
tetrasaccharide molecule.[22] The specific binding is mediated by attachment of 
β-galactosides on the carbohydrate lying within the convex groove to one or 
more of the 4 carbohydrate binding region subsites. 
1.1.2.2  Galectin β-Galactoside Binding Avidity 
Individual galectins have different binding avidities for different β-galactosides 
influenced by external conditions like temperature and ligand concentration. [12] 
Most single molecule galectin-ligand binding avidity is less that for protein-
protein interactions. [22] Binding avidity may be considerably increased by 
dimerization or cross-linking of the galectins. For example, monomeric Gal-1 has 
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a weak affinity for lactosamine residues but is increased in its dimeric form. [23] 
Galectin-3 (Gal-3) is an example of a galectin whose biological properties are 
dependent on self-association via its N-terminus into large lattices which greatly 
increases its binding avidity. [24-26] The N-terminus of Gal-3 does not contain the 
CRD, therefore when N-terminae self-associate oligomers are formed cross-
linking many oligosaccharides within the glycocalx on the extracellular 
membrane (ECM). [27] 
1.1.2.3  Cellular and Tissue Location of Mammalian Galectins 
Galectins are synthesized on cytosolic ribosomes and can move from the cytosol 
to the nucleus, remain in the cytoplasm or move to the cell surface. [18] Post 
translational modification of galectins appears to be restricted to 
phosphorylation. [18, 28]  Galectins lack a signal peptide and move to the cell 
surface via a non-classical (non-Golgi, non-endoplasmic reticulum directed) 
pathway.[29] The ability to move within these intra and extracellular 
compartments enables galectins to have a wide range of intra and extracellular 
functions. [30] For example, Gal-3 has the ability to influence nuclear RNA splicing 
as well as influencing cell adhesion outside the cell. [31, 32] Some galectin 
members are distributed widely in different tissues and cell types whereas 
others are more selectively expressed [Table-2].  Galectin 1, 3 and 9 are also 
stable and biologically active in a soluble form.[33] 
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Table 2: Tissue and cellular distribution of Mammalian Galectins. Gal-3 is 
expressed on most leucocytes and most epithelial surfaces. In addition to basal 
expression Gal-3 expression can be increased under inflammatory conditions. 
Adapted from Than et al.[34] 
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1.1.2.4   Galectin function –‘Optimising molecules’ 
That galectins are widely present throughout nature suggests an important role 
in the life of organisms. In vitro data has led galectins to be linked with important 
roles in inflammation, cancer and developmental biology.[18] The generation of 
Gal-1 knockout and Gal-3 knockout (Gal-1 -/- and Gal-3 -/-) mice has demonstrated 
absence of one or both genes together does not significantly affect lifespan or 
fertility of mice under animal house conditions. [35] The specific tissue and 
cellular distributions of Gal-1 and Gal-3 and their different roles within an 
organism explain why there is no evidence of functional redundancy regarding 
these 2 galectins. [18] A review of Gal-1 -/- and Gal-3 -/- mice suggests that 
galectins may be ‘optimising molecules’. This theory would hold that galectins 
are not required for absolute function but for most efficient function upon 
encountering a ‘hit’ like cancer or inflammatory disease.[35] As the role of 
galectins in disease is elucidated, they present themselves as potential 
therapeutic targets for translational research. Galectins 1, 3 and 9 are the most 
researched and described of the galectin family.[36] 
1.2  Galectin-3 (Gal-3) 
Gal-3 is the only member of the chimeric group of the galectin family, a protein 
of 29-35 kilodaltons (KDa).[37] Gal-3 was first identified on the surface of murine 
thioglycollate-elicited peritoneal macrophages.[38] This gave some important 
initial information, that it is expressed on cells of the monocyte/macrophage 
lineage and that it was expressed in an inflammatory model. Gal-3 has one 
carbohydrate recognition domain (CRD) consisting of approximately 130 amino 
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acids on the C-terminal and is joined to a 110-130 amino acid N-terminal domain 
with tandem repeats of short amino acid segments.[24] The N-terminal end is rich 
in proline, glycine and tyrosine residues and is responsible for many of the 
intracellular biological activities compared to the C-terminus which contains the 
CRD.[24] The N-terminus is involved in higher order oligomerisation resulting in 
multivalent Gal-3 molecules with multiple CRDs.[25] The importance of this, as 
discussed previously, is the ability to increase avidity for β-galactosides in the 
glycocalx, crosslinking oligosaccharides on cell surfaces.[27]  Gal-3 is principally 
found in endothelial cells, epithelial cells and most immune cells including 
fibroblasts, lymphocytes, neutrophil and monocytes/macrophages. [39-44] Within 
these cells it can be expressed on the cell surface, in the cytoplasm, the nucleus 
as well as cytoplasmic organelles including phagosomes and mitochondria.[45, 46]  
Gal-3 binds glycoconjugates, like laminin, on the extracellular cell surface and 
matrix via its CRD.[47] The extracellular biological actions of Gal-3 are dependent 
on its ability to self-associate into higher order oligomers. [26] Gal-3 oligomers 
mediate cell-cell and cell-ECM adhesion; acting as a bridge to bind cells together 
and initiate intracellular signalling. Gal-3 has emerged as a central regulator of 
both acute and chronic inflammation via its ability to activate, induce migration 
and regulate apoptosis in immune cells.[36, 37] Gal-3 has often been designated a 
pro-inflammatory galectin (in contrast to Gal-1), however Gal-3 also provides a 
role in the resolution of inflammation and tissue repair.[36, 37] Clearance of Gal-3 
is predominantly hepatic but is found in the urine, there is no data on renal 
clearance of Gal-3.[48, 49]  The presence of Gal-3 and its secretion from transitional 
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cell epithelium of the lower urinary tract would make assessment of true Gal-3 
clearance difficult unless   labelled Gal-3 is used. [50] 
1.2.1  Gal-3 and Inflammation 
After an early role in the developing embryo Gal-3 has a relatively limited role 
under resting conditions until inflammation disrupts the basal state. Gal-3 has a 
role in kidney organogenesis in both murine and human kidneys.[51, 52]   Human 
kidneys express Gal-3 in tissues of the mesonephric duct origin from 5 weeks of 
age onwards.[51] Once the kidney is mature Gal-3 expression becomes limited to 
epithelial distal convoluted tubule and collecting duct cells within the nephron 
and ureter.[51] The Gal-3 -/- mouse  is phenotypically identical to a WT mouse of 
the same background under animal house conditions until 6 months of age apart 
from subclinical differences in kidney structure and function.[53]  Bichara et al 
reviewed differences in renal structure and function between WT and Gal-3 -/- 
mice.[54] Gal-3-/- mice have approximately 11% fewer glomeruli than WT mice 
reflecting Gal-3’s role in nephrogenesis.[54] Bichara’s group found a 
compensatory kidney hypertrophy in Gal-3-/- mice. These differences were not 
physiologically relevant under animal house conditions. Gal-3-/- mice and WT 
mice were found to have similar glomerular filtration rates (GFR), bicarbonate 
excretion but an increased urinary chloride excretion.[54] Bichara found under 
low salt conditions there were pathological differences between WT and Gal-3 -/- 
mice. Gal-3-/- mice fed a chronic low sodium diet developed volume contracture 
with less extracellular fluid than WT mice.[54]  The resting state increased urinary 
chloride loss also tended to a lower BP in Gal-3-/- mice under standard 
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conditions.[54] After 6 months of age Gal-3-/- mice develop fatty infiltrates in their 
livers resembling human non-alcoholic steatohepatitis.[55] underlying Gal-3’s role 
in removing advanced glycation end products (AGE) and advanced lipoxidation 
end products (ALE).[55]  Whilst WT and Gal-3-/- mice are similar prior to 6 months 
of age under animal house conditions there are significant differences between 
the two in the generation and resolution of inflammation [Table 3].  
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Table 3: Gal-3 is involved in the generation and resolution of inflammation. The 
table above describes the effect of addition of recombinant Gal-3 to leucocytes 
and Gal-3-/- mice subject to inflammatory models. Generation of inflammation, 
Gal-3-/- mice have a reduced leucocyte infiltration in models of pneumonia and 
peritonitis.[56, 57] In vitro recombinant Gal-3 promotes adherence of neutrophils 
to ECM proteins (laminin and fibronectin), and endothelial cells.[47] Gal-3 is a 
chemoattractant for monocytes and macrophages.[58] Gal-3 induces mast cell 
degranulation.[59] Resolution, Gal-3 has a role in tissue repair and fibrosis 
stimulating fibroblasts to produce collagen and promoting macrophage 
differentiation towards a ‘pro-fibrotic’ alternate (M2) differentiation.[60] The 
result is that Gal-3-/- mice exhibit impaired wound healing.[61, 62] Gal-3 also plays a 
role on the resolution of inflammation by binding and clearing AGE and ALE seen 
in conditions like diabetes.[63] Gal-3-/- mice in a model of diabetic nephropathy 
develop worse proteinuria and accelerated glomerulopathy.[64] Gal-3 acts as a 
pattern recognition receptor (binds Klebsiella, Salmonella and E.Coli) and is a 
negative regulator of lipopolysaccharide mediated inflammation. [65, 66] 
Consequently Gal-3-/- mice have an increased susceptibility to endotoxic 
shock.[65] Macrophage phagocytosis is optimised by Gal-3 and Gal-3-/- mice 
demonstrate a reduced kupffer cell phagocytosis of red blood cells in 
experimental haemolytic anaemia.[67]  
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1.2.1.1   Leucocyte Expression of Gal-3  
Most cells involved in the generation and resolution of inflammation express 
Gal-3. [40, 41, 68, 69] Of the Gal-3 expressing leucocytes only monocytes and 
macrophages have been documented to have the ability to secrete Gal-3.[70],[71] 
Most leucocytes can express Gal-3 on their extracellular membrane via ‘non-
classical’ transport and could plausibly secrete Gal-3.[36] Gal-3 leucocyte 
expression is not a constant and can rapidly change, which is partly regulated at 
the level of transcription, reflecting Gal-3 role as an immediate early gene (IEG) 
rapidly responding to changes in the cells local environment.[72] 
1.2.1.1.1   Endogenous and Exogenous Gal-3 and Leucocyte 
Behaviour 
This thesis will focus on the effects of Gal-3 and monocyte/macrophage function 
but an overview below demonstrates that Gal-3 has influence on many leucocyte 
functions. As discussed previously this influence is not absolute but often as an 
optimising molecule. Endogenous and exogenous effects of Gal-3 on leucocyte 
behaviour under inflamed conditions are shown below [Table 4, 5]. Gal-3 does 
have some pro-inflammatory effects e.g. inducing superoxide production in 
neutrophils and monocytes. There are also effects that will promote resolution 
of inflammation e.g., the promotion of macrophage phagocytosis. 
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Table 4: Actions of exogenous Gal-3 on Leucocytes, recombinant Gal-3 induces 
IL-2 production, Ca2+ influx and protects activated T cells from apoptosis.[73, 74] In 
mast cells recombinant Gal-3 induces histamine release.[75] The effects of 
exogenous Gal-3 on neutrophil function are arguably pro-inflammatory inducing 
oxidative burst, IL-8 production, L-selectin shedding and protection from 
apoptosis.[57, 71] Monocytes migrate towards and induce superoxide anion on 
exposure to Gal-3.[41, 58] 
 
Table 5: Actions of Endogenous Gal-3 on leucocytes. Gal-3 is necessary for IL-2 
dependent primary T cell growth.[42] Macrophages deficient in Gal-3 have 
impaired phagocytosis; Gal-3 enhances phagocytosis of apoptotic neutrophils.[58, 
76] Gal-3 induces the pro-fibrotic ‘alternative macrophage activation and reduces 
pro-inflammatory cytokine production on stimulation of macrophages by LPS.[65, 
77] Gal-3 has a role in modulating Th response in dendritic cells.[78] 
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1.2.1.1.2   Gal-3 Regulation of Monocyte/Macrophage Subset 
Phenotype 
Monocytes have been known to be a part of the inflammatory response since 
the 1970’s when proliferation in bone marrow of monocytes was observed in 
inflammatory stimuli resulting in a monocytosis.[79] In 1989 heterogeneity of 
monocytes was observed for the first time.[80]  Both human and murine 
monocytes can be distinguished into distinct subsets based on surface 
expression of specific markers. Each monocyte subset has a distinct 
pathophysiological role. Elevated monocyte levels have been found in various 
human pathological conditions including cardiovascular disease and CKD.[81-84]  
1.2.1.1.2.1   Human and murine monocyte subsets 
1.2.1.1.2.1.1   Murine Monocyte Subsets 
 Ly6chigh monocytes are preferentially recruited into inflamed tissue via 
interaction of chemokine receptor 2 (CCR2).[85] Ly6Chigh monocytes differentiate 
to mature inflammatory (M1) macrophages (distinguished by secretion of pro-
inflammatory TNF-α, IL6 and contribute to T-cell activation). Ly6Clow monocyte 
subsets secrete the anti-inflammatory cytokine IL-10 on in vivo bacterial 
infection. Upon encountering vascular inflammation they are recruited into 
tissue and differentiate predominantly into M2 macrophages which secrete anti-
inflammatory cytokines and contribute to tissue repair.[86] Because Ly6Clow have 
lower expression of adhesion molecules they are less likely to transmigrate and 
more likely to patrol the vascular endothelium [Table 6]. Ly6Cint /mid monocytes 
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are pro-inflammatory and the human equivalent is the CD14++/CD16+ 
‘intermediate’ monocyte that is found to be elevated in human CKD and 
significantly associated with adverse cardiac events in both haemodialysis and 
pre-dialysis CKD cohorts.[81, 87]  
 
 
Table 6: Human and Murine monocyte subsets, cell surface markers and patho-
physiological role. 
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1.2.1.1.2.2 Gal-3 and Monocyte/ Macrophage differentiation 
There is evidence that Gal-3 is important for monocyte/macrophage behaviour. 
Circulating human monocytes increase expression of Gal-3 as they differentiate 
into macrophages and Gal-3 is downregulated when they differentiate into 
dendritic cells.[41, 88] Both monocytes and macrophages can secrete Gal-3 to act 
in an autocrine or paracrine fashion. Gal-3 can promote monocyte-monocyte 
attachment leading to polykaron (multinucleate giant cell) formation, a 
phenotype associated with M2 macrophage activation.[89] 
The initial inflammatory response in inflamed tissue is characterised by pro-
inflammatory ‘classically activated’ M1 macrophages. The resolution phase of 
inflammation is characterised by ‘alternatively activated’ M2 macrophage 
accumulation. Macrophages can differentiate into either subset depending on 
their local micro-environment. M1 macrophage differentiation can be induced 
by exposure to Th1 cytokines (IFN-λ, IL-12) or microbial agents.[90, 91] M2 
macrophage differentiation can be induced by Th2 cytokines IL-4 and IL-13.[92, 93] 
1.2.1.1.3 Gal-3 and Leucocyte-Endothelial Interactions 
Both in vitro and in vivo models have suggested that Gal-3 increases leucocyte 
adherence to endothelium, endothelial transmigration and infiltration into 
tissues under inflamed conditions.[47, 94-96] These effects appear to be mediated 
by both CRD-dependent and CRD-independent mechanisms.[47, 96] In vitro data 
includes evidence of Gal-3 promoting neutrophil adhesion to extracellular matrix 
proteins laminin and fibronectin.[47] Laminin adhesion was partly dependent on 
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the Gal-3 CRD but binding to fibronectin is independent of the CRD acting by 
increasing expression of adhesion molecule β-2 integrin.[47] Recombinant Gal-3 
mediates human neutrophil attachment to a human endothelial cell line ECV304 
monolayer.[94] The same study showed that Gal-3 played a role in β-2 integrin-
independent neutrophil extravasation, which occurred during a murine model of 
alveolar infection with streptococcal pneumonia. Gal-3 can bind major 
xenoantigen α-gal – expressed on endothelial cells.[96] A neutralising antibody to 
α-gal prevents human monocyte attachment to porcine endothelium suggesting 
this as a further mechanism of leucocyte-endothelial adhesion.[96] In vivo models 
of Gal-3’s effect on leucocyte infiltration in inflammation are described below 
[Table-7]. 
 
 
Table 7: Leucocyte recruitment and infiltration in Gal-3-/- mice subject to 
inflammatory disease models. The Gal-3-/- mouse demonstrates reduced 
leucocyte recruitment in models of peritonitis, pneumonia and toxoplasma 
infection.[56, 78, 95, 97] 
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1.2.1.2   Gal-3 and the Resolution of Inflammation 
1.2.1.2.1 Gal-3 as a Scavenger Receptor for AGE 
Accumulation of AGE plays a role in the structural and pathological changes 
associated with diabetes and ageing. AGE are reducing sugars complexed with 
proteins to form irreversible post-translational modifications. AGE receptors 
internalize and either degrade or elicit pro-inflammatory pathways (Receptor of 
AGE (RAGE) receptor pathway).  There is evidence of a protective effect of Gal-3 
against diabetic nephropathy and lipid induced glomerular injury.[98, 99] The 
protection may be mediated by the ability of Gal-3 to function as a receptor to 
internalize and ultimately degrade AGE / ALES’s.[100] In 1995 Vlassara et al. 
demonstrated that the 90 kilo Dalton (kDa) AGE receptor had sequence 
homology with Gal-3 and that Gal-3 could bind AGE modified Bovine Serum 
Albumin (AGE-BSA).[63] Saturable association kinetics demonstrated an 
association for free recombinant Gal-3 and stronger association with membrane 
bound Gal-3.[63] Gal-3 is not a distinct AGE receptor but forms part of a larger 
AGE receptor complex functionally interacting with AGE-R1 and AGE-R2. Gal-3’s 
role as an ALE receptor was suggested by the interaction with Gal-3 and gp-
90/Mac-2 binding protein.[101] The gp-90/Mac-2 binding protein has sequence 
homology to scavenger receptors that recognise oxidated or acetylated low 
density lipoprotein (LDL). Zhu et al  endorsed this hypothesis using Chinese 
hamster ovary  (CHO) cells overexpressing Gal-3.[101]  When exposed to labelled I-
AGE-BSA the Gal-3 formed a ligand with AGE- BSA, the receptor ligand complex 
was endocytosed and subsequently underwent lysosomal degradation.[101] The 
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role of Gal-3 as an ALE receptor and degrader was suggested using CHO cells 
overexpressing Gal-3 cultured with radioactive labelled acetylated and oxidised 
LDL where the same degradation process was observed. Cholesterol esters 
within the CHO cells gave a similar appearance to foam cells. This appearance 
prompted Zhu et al to hypothesize that Gal-3 may be involved in 
atherogenesis.[101] This is corroborated by Gal-3 acting as scavenger receptor 
(highly expressed on macrophages) internalising LDL cholesterol in the process of 
‘Foam Cell’ formation.[64] Gal-3 is expressed in human atherosclerotic plaques 
and inhibition of Gal-3 reduces atherosclerosis in apolipoprotein deficient 
mice.[102, 103] 
Gal-3 is an AGE receptor leading to AGE degradation in vitro and Gal-3 is up-
regulated in the glomerulus under diabetic conditions.[99] Pugilese at al 
demonstrated early glomerular Gal-3 expression at 2 months with an increasing 
degree of staining apparent up to 12 months of age in a rat model of 
experimental diabetes (streptozotosin administration). A non-diabetic control 
could only show Gal-3 expression after 12 months of age.[100] Other components 
of the AGE receptor complex (p60 and p90) were up-regulated in a similar 
fashion in diabetic rats.[100]  
Pugilese et al. hypothesized that Gal-3 expression would protect against the 
renal effects of diabetes (mesangial matrix deposition and other glomerular 
changes) via its role as an AGE-receptor / degrader. [99] WT and Gal-3 -/- mice 
were subjected to the streptozotosin model of diabetes and sacrificed at 4 
months. Diabetic WT and Gal-3 -/- mice had equivalent metabolic derangement, 
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growth and serum creatinine. However, renal histology revealed Gal-3 -/- mice 
had a significantly increased mesangial fractional area (+52%) vs diabetic WT. 
Diabetic Gal-3-/- mice had significantly raised total AGE levels (+42%) and raised 
peripheral and mesangial AGE staining vs diabetic WT mice.[99] 
Gal-3 -/- mice develop proteinuria when exposed to high levels of AGE, 
independent of diabetes.[104] N-carboxymethyllsine (CML)-modified mouse 
serum albumin (MSA) was used by Pugilese’s group as an exogenous AGE.[104] 
Gal-3-/- and WT mice were exposed to this artificial AGE for 3 months giving 
serum AGE levels equivalent to those in the streptozotosin model.[104] At 7 
months the mice were sacrificed, Gal-3-/- and WT mice had equivalent serum 
creatinine but Gal-3-/- mice had significantly more proteinuria.[104] Gal-3-/- mice 
had higher circulatory AGE levels, renal tissue AGE expression and kidney 
Nuclear Factor Kappa Beta (NF-κβ) activity vs WT –CML – MSA exposed mice 
suggesting a protective role of Gal-3 in AGE mediated disease.[104] 
1.2.1.2.2  Gal-3 and Age mediated disease: Type 2 Diabetes 
Human Gal-3 is up-regulated in type 2 diabetes and proteinuria correlates to Gal-
3 expression.[50, 64, 98]  Gal-3 is not expressed under normal conditions in the adult 
human glomerulus. It is only constitutively expressed in the intercalated cells of 
the collecting duct.[51] Animal models of renal Ischaemia–reperfusion [105] and 
mesangial-proliferative glomerulonephritis[106] have shown Gal-3 expression is 
transiently up-regulated in distal and proximal tubules and expressed in 
macrophages infiltrating the glomerulus.  Kikuchi et al. applied anti-human Gal-3  
immunohistochemical staining on 37 human renal biopsies (9 - type 2 diabetes, 9 
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- IgA nephropathy, 6 - membranous nephropathy, 5- minimal change disease and 
17 - normal renal tissue from nephrectomies as control specimens).[107]  In 
control biopsies there was no evidence of anti-Gal-3 antibody staining in 
glomeruli, PCT or interstitium, though weak staining was present in the distal 
convoluted tubule and collecting duct.[107]  Glomerular anti-Gal-3 antibody 
positive cell infiltration was noted in 12 of the 37 biopsies. (6/9- type 2 diabetes 
mellitus, 3/9-IgA nephropathy, Mb N- 1/6 minimal change – 0/5). The ratio of 
glomeruli with Gal-3 + cell infiltration: normal glomeruli were significantly higher 
in diabetic patients (22.5%). Gal-3 positive cells co-localised on double 
immunofluorescence with CD68 suggesting the infiltrating cells were 
macrophages expressing high levels of Gal-3.[107] The degree of proteinuria from 
diabetic patients correlated with the amount of Gal-3 expression on renal 
immunohistochemistry (p<0.001). The more Gal-3 positive cell infiltration the 
higher the amount of proteinuria.[107] Baseline measurements of the diabetic 
patient’s glycated haemoglobin (HBA1c) and glomerular filtration rate (GFR) 
showed no correlation with the amount of Gal-3 positivity. The main histological 
parameter associated with glomerular Gal-3 positivity was the degree of 
interstitial fibrosis – significantly higher in Gal-3 positive samples.[107]   
Human mesangial cells cultured with rosiglitazone in the presence of AGE up-
regulate Gal-3 in a time and dose dependant manner.[108]  Rosiglitazone (a 
peroxisome proliferator-activated receptor agonist) has been shown to 
ameliorate diabetic nephropathy and reduce circulating levels of serum AGE-
peptide. Sun et al. investigated the in vitro effects of rosiglitazone on human 
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mesangial cells Gal-3 expression.[108] Human mesangial cells were incubated with 
different concentrations of AGE modified Bovine Serum Albumin (AGE-BSA) (0, 
50,100,200 and 400 mg/l) for different times (0, 24, 36, 48 and 72 hours) and 
exposed to AGE-BSA in with varying concentrations of rosiglitazone (1, 10, 100 
µmol/L).[108]  AGE modified-BSA up-regulated Gal-3 expression in cultured 
mesangial cells in a dose and time dependent manner. Adding rosiglitazone in 
the presence of AGE-BSA independently increased the mRNA and protein 
expression of Gal-3 in a dose dependent manner.[108] Interestingly, the use of 
rosiglitazone is now subject to controversy due to increased cardiovascular risk. 
Gal-3 has recently been demonstrated to be a novel prognostic marker for heart 
failure.  
Gal-3-/- mice demonstrate accelerated lipid induced glomerular injury.[109]  Gal-3 
has been shown to act as a receptor for ALE.[109] ALE contributes to disease in a 
variety of ways including atherosclerosis, pro-inflammatory pathways and can 
mediate glomerular injury. WT mice fed on a high fat diet increase renal Gal-3 
protein expression and Gal-3 mRNA up-regulation.[109] Iacobini et al. fed Gal-3-/- 
mice a high fat diet showed accelerated glomerular injury associated with 
glomerular cell apoptosis and more pronounced matrix production.[109] 
Compared to WT controls, serum and kidney ALE/AGE content was raised in Gal-
3-/- mice.  AGE receptor and Scavenger Receptor expression (except SRA1), 
systemic and renal tissue oxidative stress and macrophage infiltration was raised 
in the Gal-3-/- mouse model fed on a high fat diet compared to WT mice fed high 
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fat diet.  The authors speculated that this had important implications for both 
local renal and systemic disease mediated by ALE’s and AGE’s.  
1.2.1.3  Regulation of Gal-3 under inflammatory conditions  
Cellular expression of Gal-3 is regulated at least in part at the level of 
transcription.[110] Gal-3 signalling pathways are not fully understood despite 
evidence for different external stimuli regulating cell expression.  Soluble Gal-3 is 
raised in inflammatory conditions associated with raised cytokines and AGE. The 
mouse Gal-3 gene (LGALS3) was described by Rosenburg et al. in 1993 [111] and 
the human Gal-3 gene was described by Kadrofske 1998 [72]. Gal-3 is encoded by 
a single gene within the human gene on chromosome 14 and is composed of 6 
exons and 5 introns over 17 kilobases.[72] There are 2 transcription initiation 
sequences in the Gal-3 promoter region. The human Gal-3 gene promoter has 
multiple GC box motifs for binding transcription factor Sp1 in common with 
constitutively expressed ‘housekeeper genes’.[72] When serum starved cells 
(fibroblasts) are exposed to serum, Gal-3 transcription is increased.[110]  In view 
of this LGALS3 is designated an IEG. IEG are genes which are activated transiently 
and rapidly in response to a wide variety of cellular stimuli. Several transcription 
factor binding sites on the Gal-3 promotor have been identified.[72] 
1.2.1.3.1   Gal-3 under Cyclic-AMP/ NF-κβ/ Rel control 
There is evidence for Gal-3 being a putative gene target for Nuclear Factor Kappa 
Beta (NF-κβ)/Rel transcription.[73] Hsu et al. demonstrated Gal-3 upregulation in 
human T-cells infected with HTLV-1 virus.[73] Unlike monocytes, macrophages 
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and neutrophils Gal-3 is minimally expressed in lymphocytes. Infection of T-
lymphocytes with HTLV-1 virus induces gene upregulation via the transactivating 
factor TAX.[73]  TAX itself exerts its effect via 2 transcription pathways CREB/ATF 
and NFκβ/Rel pathways.[73]  Both CREB/ATF and NF-κβ binding sites have been 
identified within the mouse Gal-3 promoter. [112] Compared to the efficacy of TAX 
protein to increase Gal-3 expression, CREB/ATF induces a similar expression 
whilst NF-κβ/Rel did not increase Gal-3 to the same extent.[73] NF-κβ/Rel exerting 
control over Gal-3 expression would fit with observations of Gal-3 as an IEG with 
up-regulation in inflammatory conditions.[72] NF-κβ/Rel is a signal transducer in 
immediate early phases of immune responses and conditions of oxidative 
stress.[113] Raised AGE in chronic kidney disease can be bound by several AGE 
receptors including receptor of advanced glycation end products (RAGE) and Gal-
3 (designated AGE receptor 3). RAGE is a member of the immunoglobulin 
superfamily and is expressed on the extracellular membrane on various cell 
types as well as existing in a soluble form. The RAGE receptor has a cytoplasmic 
tail which transduces intracellular signalling following AGE binding to the 
receptor.[114] Membrane bound Gal-3 internalises AGE following binding and 
detoxifies it without inducing intracellular signalling. However RAGE exerts a 
cascade of pro-inflammatory signalling following binding including NF-κβ 
signalling. Given that Gal-3 is potentially under NF-κβ /Rel control and has 
beneficial opposite effects in AGE scavenging and detoxifying, it could be Gal-3 is 
upregulated by RAGE via the NF-κβ pathway as a protective feedback. A human 
immortalised monocytic cell line (THP-1) exposed to AGE (carboxymethyllyseine) 
modified human serum albumin demonstrated p38 MAPK activation mediating 
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RAGE induced NF-κβ dependent secretion of pro-inflammatory cytokines.[115] In 
2003 another group exposed THP-1 cells to phorbol ester and demonstrated 
increased Gal-3 expression and inhibited by SB-203580, a specific p38 MAPK 
inhibitor.[116] 
1.2.2  Gal-3 and fibrosis 
Fibrosis represents the final common pathway of chronic tissue injury.[117] 
Chronic inflammation with formation of scar tissue and loss of function is a 
characteristic of many human diseases and represents a cause of morbidity and 
mortality worldwide.[118] Quiescent resident tissue fibroblasts become activated 
to a matrix secreting myofibroblast phenotype. Increased Gal-3 expression has 
been documented in tissue fibrosis and in vitro recombinant Gal-3 induces 
proliferation of myofibroblasts.[119]  
1.2.2.1  Gal-3 and Hepatic Fibrosis 
Gal-3 is implicated in and contributes to a murine model of hepatic fibrosis.[120] 
Henderson et al. induced a model of liver fibrosis (CCL-4, carbon tetrachloride) in 
WT and Gal-3-/- mice.[120] After 8 weeks of CCL-4 treatment Gal-3 was present in 
periportal and areas of bridging fibrosis in the liver. Control (olive oil treated) 
animals had Gal-3 expression limited to bile duct epithelium. Liver homogenate 
showed significantly raised Gal-3 mRNA and protein in CCL-4 treated group.[120] 
The Gal-3-/- mice given CCL-4 treatment had significantly less collagen deposition 
and less procollagen-1 mRNA compared to WT CCL-4 treated animals.[120] Gal-3-/- 
mice treated with CCL-4 had significantly less α-SMA mRNA and protein than WT 
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treated animals. WT and Gal-3-/- mice had equivalent liver injuries (defined by 
elevated liver enzymes) after intra-peritoneal administration of CCL4. Liver levels 
of TNF-α were also similar between the two groups. Macrophages from both WT 
and Gal-3-/- animals exhibited similar levels of pro-inflammatory cytokines on 
stimulation with LPS. [120]The hepatic stellate cell (HSC) is the key fibrogenic cell 
of the liver and after any liver injury HSC’s undergo activation to proliferate and 
phenotypically change into fibrogenic myofibroblasts (with increased expression 
of alpha smooth muscle actin (α-SMA))Gal-3-/- HSCs proliferate and stain +ve for 
α-SMA following co-culture with recombinant Gal-3. 
1.2.2.2  Gal-3 and Renal Fibrosis 
Progressive renal disease is the result of expansion of renal interstitial 
extracellular matrix leading to nephron loss. Okamura performed unilateral 
ureteric outflow obstruction (UUO) on WT and Gal-3-/- mice. [121]  This model 
produces progressive fibrosis of the affected kidney without significant rise in 
creatinine as the unaffected kidney can provide adequate renal function by itself. 
In the ligated kidney Gal-3 mRNA rises to a peak (95-fold increase) at 7 days post 
UUO. On immunohistochemistry Gal-3 localised to proximal tubular cells then 
infiltrating macrophages to the interstitium. In sham operated kidneys of WT and 
Gal-3-/- mice collagen levels were similar. In kidneys subject to UUO after days 14 
and 21 the collagen levels were higher and more disorganised in Gal-3-/- mice 
suggesting that Gal-3 attenuated fibrosis severity and preserved intact renal 
tubules in the later stages of the UUO model. Apoptosis (measured by TUNEL 
staining) of tubular epithelial cells was increased by 123% in Gal-3-/- murine 
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kidneys 14 days post UUO. Paradoxically despite worse fibrosis severity scores 
the Gal-3-/- kidneys 14 days post UUO had 80% less fibronectin and procollagen-1 
mRNA as determined by real time quantitative polymerase chain reaction (qPCR) 
and fewer myofibroblasts. The arrangement of collagen fibres was more 
disorganised in Gal-3-/- mice leading the author’s in the paper [121]to conclude 
that Gal-3 modulates extracellular matrix turnover. Endo-180 is an endocytic 
receptor for collagen 1 and 4. It is a key receptor for matrix degradation during 
wound remodelling. During UUO endo-180 mRNA and protein levels rise. Endo-
180 deficient mice have significantly worse fibrosis scores after UUO. Gal-3-/- 
mice have reduced endo-180 levels. Okamura et al. speculated that Gal-3 may 
crosslink α1-integrin (via its CRD) and endo-180 to facilitate collagen 
endocytosis. Both macrophages and fibroblasts can express endo-180. 
In 2008 Henderson et al. also investigated Gal-3 regulation of fibrosis in the UUO 
model of progressive renal fibrosis.[60]. Compared to sham operated animals WT 
mice with UUO had significantly more Gal-3 in renal interstitium and tubular 
epithelial cells. Whole kidney qPCR of Gal-3 mRNA showed a significant increase 
from day 3 to day 7. In contrast to Okamura et al. [121] collagen staining of the 
UUO kidneys in Gal-3-/- mice revealed reduced interstitial collagen accumulation 
compared with WT mice. Gal-3-/- kidneys subject to UUO also had significantly 
reduced procollagen-1 and αSMA (a marker of activated myofibroblasts) on 
qPCR. The authors concluded that the absence of Gal-3 gene protects against 
renal fibrosis after UUO. Disruption of the Gal-3 gene did not affect macrophage 
recruitment in the UUO model. Gal-3-/- macrophages have similar cytokine 
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responses (TNF-α, Interferon-λ) to WT macrophages on stimulation with LPS. The 
pro-fibrotic effects of Gal-3 were therefore independent of macrophage 
recruitment and inflammatory cytokine production. Levels of transforming 
growth factor beta (TGF-β) were similar between Gal-3-/- mice and WT at 3, 7 and 
14 days post UUO. The phosphorylated TGF-β ligands SMAD2 and 3 
(phosphorylated by TGF beta kinase) were also present in similar amounts. 
Disruption of the Gal-3 gene blocked renal fibrosis despite similar levels of TGF-β 
and SMAD 2 and 3. Henderson et al demonstrated that Gal-3 positive 
macrophages could activate renal fibroblasts in vitro. As previously shown 
cultured renal fibroblasts from Gal-3-/- mice were co-cultured with recombinant 
Gal-3 leading to production of α-SMA, a marker of pro-fibrotic activated 
fibroblasts. 
1.2.2.3  Gal-3 and Pulmonary Fibrosis 
Gal-3 secreting macrophages activate fibroblasts to lay down extracellular matrix 
in human pulmonary fibrosis.[122] Idiopathic Pulmonary Fibrosis (IPF) is 
characterised by epithelial cell injury with initial accumulation of inflammatory 
cells followed by deposition of extracellular matrix and fibroblast activation 
resulting in end stage fibrosis. Nishi et al. performed Broncho-Alveolar Lavage 
(BAL) (obtaining BAL fluid and alveolar macrophages) from 41 patients[122]. Eight 
patients had diagnoses of fibrotic lung disease, 6 control samples were taken 
from healthy tissue of lung in patients with lung cancer. The rest had other non-
fibrogenic lung pathologies. Gal-3 levels were higher in the BAL fluid from 
patients with IPF. The source of Gal-3 was secreted by alveolar macrophages that 
stained strongly positive for Gal-3 on immunofluorescence of BAL. The same 
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group demonstrated recombinant Gal-3 induced migration and collagen 
secretion of NIH-3T3 fibroblast cells in vitro.[123] The authors suggest macrophage 
derived Gal-3 acts on fibroblasts and resident macrophages in an 
autocrine/paracrine manner inducing TNF-α and IL-8 secretion upon 
recombinant Gal-3 stimulation of a THP-1 macrophage immortalized cell line. 
1.2.2.4  Gal-3 and Cardiac Fibrosis 
Uraemic cardiac fibrosis contributes to ‘stiffening’ of the myocardium and 
diastolic dysfunction associated with CKD. Gal-3 has been implicated in chronic 
inflammatory disease leading to fibrosis in models of hepatic, lung and renal 
fibrosis. Gal-3 mediates alternative (M2) macrophage activation, induces 
proliferation and collagen secretion in quiescent lung and cardiac fibroblasts. 
Pro-fibrotic and inflammatory multinuclear giant cell formation is associated 
with monocyte Gal-3 expression. The underlying pathology of Gal-3 mediated 
cardiac dysfunction is Gal-3 secretion from activated cardiac macrophages. 
Secreted Gal-3 acts on tissue resident fibroblasts to induce pro-collagen 
secretion and lay down. Gal-3 was first implicated in heart failure following a 
microarray analysis of genes from a rat heart failure model.[119]  Gal-3 mRNA was 
expressed 5-times greater in failing myocardium vs compensated left ventricular 
hypertrophy. In the failing rat heart myocardial tissue section, Gal-3 co-localised 
with macrophages amongst areas of fibrosis.  Human myocardial biopsy similarly 
showed correlation between presence of Gal-3, a lower ejection fraction on 
echocardiography and left ventricular hypertrophy. Sharma et al. went on to 
demonstrate that Gal-3 was not just a marker of myocardial fibrosis and 
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dysfunction but directly implicated in its pathophysiology by studying intra-
pericardial infusion of Gal-3 into normal rat hearts. The Gal-3 infusion resulted in 
a decreased ejection fraction, increased heart mass and an abundance of 
collagen 1, compared with rat hearts subjected to placebo infusion. 
1.2.2.4.1   Clinical evidence implicating Gal-3 in human heart failure 
and cardiac remodelling 
The first human clinical evidence of Gal-3 being associated with heart failure was 
published in 2006 [124], Gal-3 and NT pro-BNP (a cardiac dysfunction biomarker) 
levels were measured in 599 patients attending the emergency department with 
dyspnoea. 35% of these patients had Acute Decompensated Heart Failure 
(ADHF). Area under the curve analysis showed Gal-3 to be inferior to NT pro-BNP 
as a diagnostic biomarker of ADHF but it was superior as a prognostic marker 
(predictor of death or death/recurrent HF at 60 days in a multivariate adjusted 
analysis of the 209 subjects with HF). 240 patients from the DEAL-HF study with 
stable heart failure (New York Heart Association (NYHA) grade 3 and 4) had Gal-3 
measured and allocated to quartiles based on soluble plasma Gal-3 
concentrations.[125] Patients were followed up for a mean 4.0 years for all-cause 
mortality. Progressively higher levels of Gal-3 were associated with increased 
age, worse renal function, lower body mass index (BMI) and higher NT pro-BNP 
levels. Overall, Gal-3 remained an independent predictor of mortality in these 
stable HF patients (Gal-3 hazard ratio 1.24, 95% confidence interval 1.03–1.5 
after adjustment for age, gender, renal function and NT-pro BNP). This study also 
investigated associations between ventricular remodelling and Gal-3. In the 240 
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patient cohort serial echocardiograms were performed at baseline and 3 
monthly during follow up. At baseline mean left ventricular end diastolic volume 
(LVEDV) was measured and patients divided into 3 groups based on subsequent 
changes in their LVEDV. Those patients with increasing LVEDV over time had 
significantly higher plasma Gal-3. Multivariate linear regression analyses 
revealed that Gal-3 was positively correlated to change in LVEDV (p=0.01).   
Serum Gal-3 is associated with markers of cardiac extracellular matrix turnover 
in heart failure patients.[126] A total of 106 patients with a mean NYHA class of 2 
were recruited to have serum galectin-3, extracellular matrix including type I and 
III aminoterminal propeptide of procollagen (PINP and PIIINP), matrix 
metalloproteinase-2 (MMP-2), and tissue inhibitor of metalloproteinase-1 (TIMP-
1) assessed. After adjusting for age, sex, smoking status and NYHA functional 
class, the relationship between Gal-3 and PIIINP or MMP-2 remained significant. 
Gal-3 has been also been examined in healthy subjects for its ability to predict 
subsequent heart failure. 3353 of the Framingham community based cohort had 
Gal 3 levels measured at the 6th examination (1995-8). [127]  All prevalent heart 
failure patients were excluded (n=40), plasma Gal-3 was measured and patients 
divided into quartiles based on Gal-3 value. In multivariate analysis Gal-3 was 
positively associated with age, hypertension, BMI and negatively associated with 
estimated GFR. During a mean follow up of 8.1 years 5.1% of patients 
experienced first heart failure events. The crude incident heart failure rates 
increased with increasing Gal-3 quartiles. After multivariable adjustment Gal-3 
remained predictive of heart failure risk and an independent predictor of all-
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cause mortality. Plasma Gal-3 is now a federal drug administration (FDA) 
approved blood test for clinical use in the USA. 
1.3  Gal-3 and Chronic Kidney Disease 
1.3.1   Chronic Kidney Disease 
Chronic Kidney Disease (CKD) is a major worldwide public health problem. [128] In 
2002 the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National 
Kidney Foundation defined CKD as either kidney damage or Glomerular Filtration 
Rate (GFR) below 60 ml/min/1.73m2 for 3 or more months with or without 
evidence of kidney damage, irrespective of the cause. [129] Estimates of GFR have 
been used for epidemiological purposes including the Cockcroft Gault and the 
Modification of Diet in Renal Disease (MDRD) equations. Based on the (MDRD) 
formula the estimated GFR (eGFR) is now commonly used to describe GFR.[130] 
The United States Renal Registry (USRDS) collects annual epidemiological data on 
Chronic and End Stage Kidney Disease. Between the years 2005-2010, a 
prevalence of 6.7% of the USRDS data collection population had an eGFR of < 
60mls/min/1.73m2. However the frequency increases with age, from a 
prevalence of 0.2% (age 20-39), 2.2% (aged 40-59) and 24% (aged 60+).[131]  5 
stages of CKD have been defined based on eGFR. Prevalence of each stage in the 
study population used to get USRDS data – the National Health and Nutrition 
Examination Survey (NHANES) population is shown below from 2003 [Table 
8].[132]   
  
57 
 
 
 
Table 8: Prevalence of Chronic Kidney Disease by Stage. Data taken from 2003 
NHANES population 
 
The majority of people with stage 1-3 CKD will not progress to end stage (stage 
5) renal failure but will suffer an increased cardiovascular risk.[133] Three aspects 
of CKD are pertinent to research in Gal-3. The first is the disproportionate 
cardiovascular risk associated with CKD, the second is renal tubulointerstitial 
fibrosis in progressive CKD and the third is elevated AGE and ALE in CKD. 
1.3.2   Evidence of Elevated Circulating Soluble Gal-3 in Human CKD 
Evidence for changes in soluble Gal-3 levels in human CKD can be taken from 
data in human studies of Gal-3 and heart failure that collected baseline kidney 
function measurements. Six published papers have shown a significant inverse 
correlation between renal function and Gal-3 [Table 9]. 
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Table 9: Human studies showing significant inverse correlation between sGal-3 
and creatinine clearance or GFR. Data is taken from heart failure trials which 
collected plasma Gal-3 data and measured renal function.[125, 134-138] 
 
In 2012 plasma Gal-3 was measured on baseline blood samples of 7968 patients 
from the Prevention of Renal and Vascular End-stage (PREVEND) cohort.  Plasma 
Gal-3 was significantly associated with several clinical and biochemical 
characteristics. Multivariate analysis revealed gender, age-squared, BMI, 
triglycerides, Creatinine, Cystatin-C and C - reactive protein as independent 
correlates of plasma Gal-3.[136]  Despite clinical evidence of an inverse correlation 
between kidney function and soluble Gal-3 there has been no published data as 
to why Gal-3 is raised or its source in CKD. The relationship between raised 
soluble Gal-3 with CKD and heart failure was investigated Gopal et al. in the 
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Journal of the American Heart Association in 2012.[138] Gopal et al. noted that 
published heart failure data to date had not included a cohort of patients with 
CKD and without heart failure. Gopal’s study measured plasma Gal-3 by ELISA in 
6 groups including a group with CKD but no heart failure. The mean soluble Gal-3 
in study Group 6 (CKD without heart failure) was significantly higher than the 
control or the 4 other heart failure groups. A strong inverse relationship between 
kidney function and soluble Gal-3 existed and was unaffected by the presence or 
absence of heart failure. Gopal et al. commented on the uncertainty aetiology of 
raised soluble Gal-3 in CKD, speculating whether it is a result of decreased renal 
clearance or increased renal synthesis. 
1.3.1.1  Cardiovascular Risk in CKD 
CKD has been identified as a significant cardiovascular risk factor from early 
stages.[133] Proteinuria itself without evidence of impaired GFR is an independent 
risk factor for cardiovascular disease. As CKD progresses through stages 1-5 
there is a rise in cardiovascular mortality.[133] The CKD population have 
traditional cardiovascular risk factors but also atypical cardiac risk factors [Table 
10]. Whether Gal-3 is an atypical or ‘non-traditional’ risk factor for CKD 
cardiovascular disease is still debated. 
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Table 10: Cardiovascular risk factors in CKD.[139] Gal-3 is a potential non-
traditional risk factor for cardiovascular disease in CKD. 
1.3.1.1.1   Myocardial fibrosis in CKD 
Cardiac remodelling with left ventricular hypertrophy, diastolic dysfunction and 
myocardial fibrosis are characteristics of CKD induced cardiovascular disease. 
Myocardial biopsies of patients with CKD frequently show evidence of 
cardiomyocyte hypertrophy, myocardial fibrosis, and thickening of the 
intramural arteries and arterioles.[140] Putative factors in the development of 
cardiac remodelling in CKD are shown outlined in Table 11. Gal-3, with a role in 
both human and animal models of cardiac fibrosis, as well as elevated soluble 
Gal-3 in CKD present it as a potential contributor to uremic cardiac fibrosis. [119, 
134] 
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Table 11: Causes of Myocardial Fibrosis in CKD.[141] 
 
Diastolic dysfunction is the clinical effect of myocardial fibrosis and altered 
cardiac remodelling.[142] Diastolic dysfunction is present on echocardiographic 
assessment in 46% of patients with stage 2+3 stage CKD and 62% of patients 
with stage 4+% CKD. [142] The implication of developing diastolic dysfunction is 
serious with mortality from diastolic heart failure higher than mortality from 
systolic heart failure in CKD patients.[143]  
1.3.1.1.2  Monocyte subset phenotypic change in CKD as a 
cardiovascular risk factor 
There is an association between monocyte count and cardiovascular disease 
found in large epidemiological studies.[144-146] There is also a distinct monocyte 
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subset – the ‘intermediate’ subset that correlates with adverse cardiovascular 
events in CKD and dialysis patients.[81, 87] Gal-3 is known to influence macrophage 
differentiation, if Gal-3 has a role in directing monocyte subset change it could 
be implicated in the formation of the ‘intermediate’ monocyte subset in CKD.[77] 
This thesis will examine circulating monocyte subsets in relation to experimental 
CKD and Gal-3.  
1.3.1.2  Progressive interstitial fibrosis in CKD 
This thesis has previously described Gal-3 in fibrotic disease. Gal-3 is implicated 
in the progression of fibrotic disease including models of CKD. The final common 
pathway of progressive CKD is renal fibrosis regardless of initial cause.[147] Renal 
fibrosis includes glomerulosclerosis, tubulointerstitial fibrosis and changes to 
renal vasculature. Tubulointerstitial fibrosis found on kidney biopsy is a predictor 
of a progression towards irreversible loss of kidney function and eventually end 
stage renal disease.[117] Despite considerable research and understanding about 
the mechanisms underlying tubulointerstitial fibrosis there are no effective 
therapies to disrupt and halt this process.[147] Renal tubulointerstitial fibrosis is a 
complex process involving exposure of the renal interstitium to insults and the 
host response to these insults [Table-12]. Given the described data implicating 
Gal-3 in fibrotic mechanisms, the described elevated plasma Gal-3 in human CKD 
this thesis will review the association of Gal-3 and CKD fibrosis in experimental 
uraemia. 
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Table 12: Overview of precipitants and inflammatory responses leading to renal 
interstitial fibrosis.[148] This thesis will review whether Gal-3 is implicated in a 
murine model of experimental CKD and tubulointerstitial fibrosis.  
  
1.3.1.3   AGE and ALE in CKD 
This thesis has described Gal-3 as an AGE receptor and that renal Gal-3 
expression is elevated in the presence of excess AGE/ALE.[63, 64, 109] The author 
will now describe CKD as a disease of AGE/ALE excess.  AGE products such as 
pentosidine and carboxymethyllyseine (CML) have been consistently 
demonstrated in normoglycaemic patients with end stage renal failure[149, 150] on 
renal replacement therapy and throughout progressive chronic kidney 
disease.[151] Uraemia is also associated with ALE product accumulation. [79] 
Proteins can be modified by carbohydrates but also by lipids peroxidation 
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derivatives like malondialdehyde to form irreversible ALE.[151] In CKD patients 
ALE levels rise concomitantly with AGE suggesting a common genesis.[151] AGE 
and ALE are usually albumin adducts and hence do not undergo glomerular 
filtration and renal clearance. The raised AGE and ALE in uraemia is therefore 
unlikely to be due to reduced renal clearance.[150] AGE and ALE are both formed 
by carbonyl amine chemistry between protein residues and reactive carbonyl 
compounds (RCO).[151] In health RCO are formed constantly by metabolism of 
carbohydrates, lipids and amino acids.[150] In haemodialysis patients the levels of 
several lipid and carbohydrate derived RCO’s are elevated [Table 13]. [152-154]  
 
Table 13: Reactive carbonyl compounds derived from carbohydrates and fatty 
acids forming AGE and ALE. The underlined RCO are those found elevated in 
CKD.[150] 
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The cause of raised RCO in CKD is likely to be either due to decreased clearance 
or increased production. Uraemia is a condition of oxidative stress with raised 
levels of Reactive Oxygen Species (ROS) and lower levels of anti-oxidants. [154] 
ROS can directly modify proteins by oxidation of amino groups [155]  or indirectly 
increase levels of RCO’s which leads to generation of AGE and ALE.[156] However, 
whilst oxidative stress may contribute to a raised RCO production in uraemia 
there are ROC that are formed by oxidative stress including 3-deoxyglucosone 
and methylglyoxal. [157] Another explanation for increased levels of RCO in 
uraemia could be reduced enzymatic detoxification of RCO. RCO can be 
detoxified by different enzymatic pathways (e.g. aldose reductase, aldehyde 
dehydrogenase and glycoxylase).[157] These detoxification pathways utilise the 
redox co-enzyme glutathione. The RCO - glyoxal and methylglyoxal react 
reversibly with the thiol group of glutathione before further metabolism by 
Glyoxalases I and II into lactate and glutathione. This effectively lowers RCO 
levels. In the uraemic state there is abrogation of the activity of serum 
glutathione dependent enzymes.[158] [159] A third consideration is whether there is 
reduced renal clearance of RCO. RCO have low molecular weights and could be 
filtered at the glomerulus and undergo subsequent renal clearing.  
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1.4  Gal-3 as a therapeutic target in CKD 
The investigation and safety profiles of Gal-3 antagonists were initially 
researched in the field of haemato-oncology.  Gal-3 is overexpressed in many 
cancers and has roles in tumour transformation, apoptosis, angiogenesis, cancer 
cell adhesion and cancer metastasis.[160]  
1.4.1 Modified Citrus Pectin 
In 1992 Modified Citrus Pectin (MCP) was developed with observation of 
potential anti-metastatic properties, initially without knowledge of its Gal-3 
antagonism.[161, 162] Subsequently MCP has been demonstrated to be effective in 
vivo and in vitro against prostate cancer,[162, 163] colon cancer,[164, 165] breast 
cancer,[165] melanoma,[161, 165] myeloma[166, 167] and lymphomas. Citrus pectin is a 
complex water-soluble, indigestible polysaccharide obtained from the peel of 
citrus fruits. It can be modified by high temperature and Ph. treatment to yield a 
substance rich in β-galactose.[161] The main mechanism of action of MCP was to 
bind to Gal-3 (a β-galactoside) and inhibit Gal-3 mediated interactions in 
cancer.[168]  
Human trials of MCP demonstrated safety and dosing strategies in an oncological 
setting.  The emerging in vitro and in vivo role of Gal-3 in fibrotic disease led to 
interest in MCP being a therapeutic role in chronic fibrotic conditions of which 
CKD was one.  
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1.4.2  GCS-100 
In October 2012 an open label single group assigned phase 1 study of weekly 
administration of GCS-100 in patients with CKD was started (Clinical Trials.gov 
identifier - NCT017172480). The purpose was to evaluate the safety of GCS-100 
as a treatment for chronic kidney disease. The GCS-100 was administered once a 
week intravenously. Subjects were aged between 18-75 years old and had a 
stable eGFR (defined by CKD EPI) between 15-45 ml/min/1.73m2. The study was 
completed in June 2013 but no results have been made available. 
In April 2013 a phase 2a placebo controlled, randomised, single-blind study of 
weekly doses of GCS-100 in CKD was started (Clinical Trials.gov identifier 
NCT01843790). The primary objective of this study was to compare changes in 
eGFR from baseline to Week 8 between placebo and GCS-100 treatment. The 
secondary objective was to determine the safety and tolerability of GCS-100 
administered for 8 weeks relative to placebo. In addition, the study measured 
the effect of GCS-100 on circulating Gal-3 and other markers of disease activity. 
The study arms included a low dose GCS-100, a high dose GCS-100 and placebo 
arm. This trial is ongoing but has stopped recruiting. The results from this study 
were presented at a poster session in the November 2014 American Society of 
Nephrology (ASN) annual meeting. The abstract suggested a significant 
improvement in eGFR for the 1.5mg/m2 GCS-100 group vs placebo after 8 weeks 
treatment, p=0.45. This significant improvement was still present 5 weeks after 
treatment stopped. However, there was no significant improvement in the 
higher dosing GCS-100 group (receiving 30mg/m2). The abstract also suggested a 
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sub-group analysis demonstrated diabetic CKD patients were particularly 
protected by GCS-100 at the 1.5mg/m2 dose.  
In December 2014 a phase 2b placebo-controlled, randomized, double-blind, 
multi-centre study of GCS-100 in patients with CKD caused by diabetes was 
established (Clinical Trials.gov identifier NCT02312050). This study had a longer 
follow up and consisted of 4 arms – a placebo arm and 3 GCS-100 arms at 1 mg, 
3mg or 9 mg push injections. This trial is currently recruiting. The primary 
endpoint was a change in eGFR from screening to measurements taken at week 
26. 
In 2015 the pharmaceutical company La Jolla Pharmaceuticals® discontinued 
further recruitment into the trial after the US Food and Drug Administration 
(FDA) requested further analytical studies of GCS-100. There were no patient 
safety or pre-clinical toxicology issues raised by the FDA. There are ongoing 
clinical trials of Gal-3 antagonists in the settings of liver fibrosis, CKD and 
idiopathic pulmonary fibrosis [Table 14].  
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Table 14: Clinical trials of Gal-3 antagonists in human fibrotic disease as of 2015. 
  
1.5  Introduction Summary 
sGal-3 is elevated in human CKD and is undergoing clinical trials with the endpoint of 
ameliorating chronic interstitial fibrosis. There is no data as to why Gal-3 is elevated in CKD, 
whether the useful effects of Gal-3 (AGE scavenging) reflect the elevation of Gal-3 as an 
appropriate physiological response in uraemia or a pathological pro-fibrotic mediator of 
systemic renal and cardiovascular disease. This thesis will attempt to address some of these 
themes. 
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1.6 Hypothesis and Aims 
The author hypothesizes that soluble Gal-3 is elevated in a murine model of subacute uraemia 
and interstitial fibrosis (Adenine Diet) and that the source of Gal-3 is monocyte derived. In view 
of the data described before showing Gal-3’s role in fibrotic disease a further hypothesis is that 
Gal-3 knockout mice will be protected against the renal interstitial fibrosis associated with the 
AD. Finally we hypothesize that the protection that is inferred by absence of Gal-3 will be 
mediated by fewer leucocytes infiltrating the kidneys reflecting Gal-3’s role in promoting 
leucocyte-endothelial attachment and transmigration.  
1.6.1 Aims 
1) To perform the Adenine diet and optimise age of mice and duration of diet to enable 
incorporation of Gal-3-/- mice. 
2) To measure both plasma soluble and solid organ Gal-3 in WT mice fed AD 
3) To measure circulating monocyte Gal-3 and monocyte subset phenotype in both WT and 
Gal-3-/- mice fed AD. 
4) To measure differences in weight, plasma Cr, histological tubulointerstitial injury and 
markers of fibrosis between WT and Gal-3-/- mice fed SD and AD. 
5) To measure differences in leucocyte-endothelial interactions between WT and Gal-3-/- 
mice in the cremasteric microcirculation and renal interstitial monocyte/macrophage 
accumulation. 
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Gal-3 expression in an experimental 
model of uraemia 
 
 
 
 
 
 
 
 
 
Chapter 2 
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Chapter 2: Gal-3 expression in an experimental model of uraemia 
2.1 Background 
Whilst soluble Gal-3 (sGal-3) has been demonstrated to increase in human CKD 
there is little animal data to suggest a similar pattern in experimental chronic 
uraemia.[125, 134-138] The cause of elevated sGal-3 in human CKD is not understood 
but already Gal-3’s association with fibrotic disease has led to human trials of 
Gal-3 antagonists (Introduction, section 1.5.).[138] There are data on renal 
interstitial Gal-3 expression in a rat model of acute kidney injury (renal 
ischaemia/reperfusion injury) but there is none in relation to plasma soluble Gal-
3 in uraemia.[105] Progressive renal interstitial fibrosis is the histological endpoint 
of the majority of human chronic kidney disease (CKD) regardless of 
aetiology.[169] A non-uremic animal model of progressive obstructive renal 
fibrosis (the unilateral ureteric obstruction model (UUO)) has been published 
examining Gal-3’s role in the promotion of renal fibrosis and suggested that the 
absence of Gal-3 ameliorates the fibrotic effect of ureteric obstruction.[60, 121] It is 
not known how the addition of the uraemic milieu affects renal and systemic 
Gal-3 expression and renal interstitial fibrosis. This chapter presents data on 
plasma sGal-3, circulating monocyte Gal-3 concentrations and solid organ Gal-3 
expression in experimental uraemia using the AD model. 
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2.1.1  Chronic Kidney Disease: Adenine Diet (AD). 
The AD model of CKD is well established in rodents.[170] The AD is a model of 
nephrolithiasis with intraluminal tubular crystal deposition and a model of florid 
renal tubulointerstitial fibrosis and progressive uraemia.[171]  
2.1.1.1  Adenine Phosphoribosyl transferase deficiency. 
A direct human correlation to the accumulation of 2, 8 – dihydroxyadenine 
(DHA) crystals within the nephron is limited to a rare autosomal recessive 
condition called adenine phosphoribosyl transferase deficiency (APRT 
deficiency).[172] The largest case series of APRT deficiency was published from 
Japan and estimated  that up to 1% of the population carry an APRT mutation as 
a heterozygote.[173] Few patients are diagnosed with APRT deficiency compared 
to the prevalence of the mutation, suggesting it is underdiagnosed.[174] The 
clinical presentation in human APRT mutation homozygotes is variable in the age 
at presentation and severity of disease phenotype. This is due to differences in 
the ability of an individual to saturate urinary DHA.[175] Some homozygotes are 
asymptomatic whilst others have significant childhood and adult nephrolithiasis 
which progresses to end stage renal failure.[175] Recurrence of DHA crystals in 
renal transplants of APRT deficient patients is also described.[176, 177] Treatment 
of APRT deficiency with allopurinol, if diagnosed prior to significant 
nephrolithiasis, can prevent and even reverse long term renal damage.[178]  
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2.1.1.2  Renal interstitial macrophage infiltration and fibrosis in the AD. 
The AD model in mice reflects a rare human nephrolithiasis, but it is the renal 
macrophage infiltration, tubulointerstitial inflammation and fibrosis elicited by 
DHA nephrolithiasis that makes it more comparable to  human CKD including 
diabetic nephropathy, IgA nephropathy and lupus nephritis.[179-182]  As a model of 
renal interstitial macrophage infiltration, progressive tubulointerstitial fibrosis 
and uraemia it correlates with advanced CKD. Renal interstitial fibrosis is 
accompanied by leucocyte interstitial infiltration with chemokine and cytokine 
generation from these cells.[183, 184]  Tamura et al. sought to define macrophage 
and chemokine pathways leading from DHA tubular stone formation to 
progressive renal interstitial fibrosis.[170]  At day 7 of feeding 0.25% AD to C57B/6 
WT mice birefringent crystals of DHA were observed in harvested renal tubules. 
At 14 days AD there was a marked infiltration of macrophages into the renal 
interstitium. Renal tissue mRNA levels of macrophage associated chemokines 
and cytokines -chemokine receptor 2 (CCR2), monocyte chemotactic protein-1 
(MCP-1), Interleukin – 1β (IL-1β) and chemokine (C-C motif) ligand 5 (RANTES) 
were significantly elevated from day 7 of the diet and increased up to 28 days of 
feeding. Gal-3 expression was not undertaken in this study. Tamura et al. 
concluded that localised intraluminal tubuloepithelial inflammation elicited by 
physical damage from DHA crystals results in tubuloepithelial release of MCP-1 
and (transforming growth factor beta TGF-β). This local inflammatory response is 
then amplified by the subsequent influx of monocyte/macrophage lineage cells 
inducing collagen laydown by activated interstitial fibroblasts.[170] 
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Tubuloepithelial expression of MCP-1 and accompanying macrophage infiltration 
are elevated in the UUO model of progressive interstitial fibrosis.[185] In the UUO 
operated kidney infiltrating macrophages secrete humoral factors TGF-β, TNF-α 
and fibroblast growth factor that attract and activate renal fibroblasts to 
produce collagen and propagate fibrosis.[186, 187] Proximal tubular cells can 
undergo epithelial-mesenchymal transition (EMT) which potentiates fibrosis and 
is established in the UUO model of renal fibrosis. EMT has not been defined in 
the AD model.[187, 188] The AD has an advantage over the UUO model by 
generating uraemia with interstitial fibrosis and allowing the interaction of 
uraemia and fibrosis to be observed. This is useful whilst studying Gal-3 because 
a hypothesis for this thesis is that elevated Gal-3 in CKD is derived from 
circulating monocytes and the observed monocyte subset phenotypic change in 
CKD promotes renal interstitial fibrosis.  
2.1.1.3  Pathophysiology of the AD: the Polyamine Pathway. 
Mammals produce adenine endogenously as a result of the polyamine pathway.  
Adenine and 5-phosphoribosyl-1-pyrophosphate are salvaged by the purine 
enzyme APRT to adenine monophosphate (AMP), which is not harmful.  When 
functional APRT is absent, adenine becomes a substrate for xanthine 
dehydrogenase which oxidises adenine into 2, 8-dihydroxyadenine (DHA) [Fig 1]. 
Rodent APRT deficiency can be absolute, in a knockout model described by 
Stockelmen et al., or functional in any WT rodent given sufficiently high oral 
administration of adenine.[172] DHA has a low solubility and precipitates in renal 
tubules having been filtered through the glomerulus. Rodents lacking APRT and 
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AD treated animals demonstrate nephrolithiasis with extensive tubular 
dilatation, inflammation, tubular necrosis, interstitial fibrosis and accompanying 
renal failure. C57B/6 mice fed 0.25% AD over 4 weeks demonstrate progressive 
macrophage and fibroblast infiltration into renal interstitium from 1-2 weeks. 
Infiltrating macrophages respond to increased expression of chemokines and 
cytokines including MCP-1, CCR-2, and TGF-β from renal tubular epithelium 
damaged by crystals. Tubular epithelial cells are physically stimulated by DHA 
crystals to produce the above cytokines and chemokines resulting in progressive 
peri-tubular fibrosis.[189] Biochemical and clinical data from a 0.2% AD in C57B/6 
mice has been described recently confirming a severe weight loss, elevated 
serum creatinine with polyuria and a systemically inflamed circulating cytokine 
expression [Table-15].[190] The AD is not a hypertensive model unlike the majority 
of human CKD which is associated with hypertension [Table 15]. The other 
noticeable effect of AD on WT C57B/6 mice is a weight loss phenotype which is 
seen often in advanced CKD. 
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The polyamine pathway. 
 
Figure 1: The polyamine pathway. Mammals endogenously produce adenine 
which is safely converted to AMP without consequence by APRT. When APRT is 
absent or overwhelmed (in the case of the adenine diet) adenine is metabolised 
to 2, 8-Dihydroxyadenine with resultant crystal deposition in renal tubules 
eliciting a brisk renal interstitial nephritis and subsequent interstitial fibrosis 
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Table 15: Adapted from Santana et al.[191]Clinical and biochemical data from WT 
C57Bl6 mice fed a 0.2% AD over 6 weeks compared to standard diet (SD).The 
0.2% diet induces uraemia with significantly elevated serum Cr, and a pro-
inflammatory serum profile with significantly elevated TNF-α, Il-1β, IL-6 and IL-10 
compared to SD controls.  
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2.1.1.4  AD:  Experimental protocols. 
There are publications using different strengths and durations of AD exposure in 
mice. Trial of a lower strength (0.2%) AD fed to C57B/6 WT mice over 6 weeks 
still yields significant weight loss.[191] Ting et al. set to optimise the AD in mice to 
overcome the significant weight loss and suboptimal duration of uraemia.[192] 
Prior to this paper most AD protocols had been optimised in rats and thereafter 
extrapolated to mice. Mice have an aversion to consuming adenine containing 
chow. Ting et al. included casein in the AD which reduces the adenine taste and 
smell in chow. An 8 week protocol was used with 10 day induction phase (0.3% 
AD + casein) followed by a maintenance phase of 46 days (alternating 0.15% and 
0.2% AD). This protocol has significant benefit compared to the 4 week 0.25% AD 
model because murine models of CKD need 8 weeks to develop CKD associated 
pathology like vascular calcification.[193] Mice subject to the eight week casein 
protocol had a rapid weight loss in the first 10 days of induction with 0.3% AD 
but had a stable weight during the remaining 46 days of alternating between the 
0.2 and 0.15% diet. During periods fed 0.15% AD there was a fall in measured 
urea and PTH indicating that there could be a washout period.  
Gal-3 is expressed by most leucocytes and epithelial cell surfaces.[39-41, 68, 69, 194] 
The human and murine epithelial and leucocyte Gal-3 expression is frequently 
basal but can be increased in inflammatory disorders and cancer.[195] CKD is an 
inflammatory disorder with systemic effects and renal specific effects. The AD 
model creates a uraemic milieu in which circulating leucocytes will be exposed to 
pro-inflammatory mediators whilst the kidney will have intra-luminal DHA crystal 
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deposition and secondary leucocyte infiltration.[170, 190] This chapter seeks to 
define both systemic and renal Gal-3 expression for the first time in 
experimental chronic uraemia. 
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2.2  General Methods 
2.2.1  Animal Husbandry 
All animals were kept in accordance with the Animals Scientific Procedures Act 
1986 under project licence no. 707055. Mice were housed 6 to a cage at a fixed 
temperature of 21±2oC with 40% humidity and 12 h light /dark cycle. All animals 
had free access to drinking water and standard rodent chow. The standard chow 
(SD) was obtained from Special Diet Service TM UK RM-1 diet (product number 
801002). Mice were the only animals used in the experiments contained in this 
thesis because of the availability of a Gal-3 knockout mouse.   Any morbidly ill 
animals identified after experimentation were euthanized according to protocol. 
Murine anaesthesia, intravital microscopy (IVM) and AD supplementation was 
performed by myself with supervision from Julius Kieswich.  
2.2.1.2  Anaesthesia during Experimentation 
Anaesthesia for murine experimentation was performed by intra-peritoneal 
injection of Xylazine (7.5mg/kg body weight) and Ketamine (150mg/kg). 
Following injection the level of anaesthesia was assessed and Xylazine/Ketamine 
(X/K) intra-peritoneal boluses were given until an adequate level of anaesthesia 
was established. 
  
82 
 
2.2.1.3  Adenine Diet administration 
10 week old male WT mice were fed 0.25% AD or SD over 4 weeks. All AD fed 
mice were otherwise kept in identical conditions as mice fed SD. Baseline 
demographic data including weight of the mice and weight of diet consumed 
were recorded each week. At weekly intervals mice were harvested and blood 
was taken by cardiac aspiration for plasma creatinine, Gal-3 ELISA and Flow 
Cytometry. The 0.25% AD was obtained from Special Diets Service (Company 
Number: 4225846, Product Number 823742). The AD was identical to standard 
chow (SDS RM1) apart from being pelleted as opposed to expanded and 
containing 0.25% adenine by weight. All diet was used within the expiry date of 3 
months or discarded. 
2.2.2  Murine Plasma Preparation 
Murine plasma was used for analysis rather than murine serum. Plasma is the 
liquid portion left from non-clotted blood once cells have been removed by 
centrifugation. Serum is the liquid portion left after removal of clotted blood and 
does not contain clotting factors. Mice from experimental and control groups 
were anesthetised and underwent cardiac aspiration into a 1 ml heparinised 
syringe via a 25 gauge needle. Approximately 100-500 µl of whole blood was 
obtained and kept on ice. Whole blood was centrifuged at 1000 rpm for 10 min 
at 4oC. Samples were inspected for turbidity or haemolysis. If there was evidence 
of turbidity the sample was centrifuged for a further 10 min and discarded if 
haemolysed. Acceptable clear plasma supernatant was pipetted into sterile 1.5 
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ml collection tubes and frozen at -20oC for future analysis. Samples were 
analysed within 2 weeks of collection.  
2.2.3  Plasma Creatinine Assays 
A commercial plasma Creatinine (Cr) assay was used in accordance with 
manufacturer’s instructions (BioAssay Systems, QuantiChrom™ Creatinine Assay 
Kit: Product number BA_DICT-500). Absorbance values were determined on an 
‘MRX-2’ plate reader (Dynex Technologies Ltd, Worthing UK). Data was analysed 
with ‘Revelation’ software by Dynex Technologies Ltd. OD values were 
determined by reading the absorbance at 450 nm as the primary wavelength and 
650 nm as the reference wavelength. Blank wells were subtracted from the 
sample well value. Intra and inter-assay coefficient of variation from samples 
was measured and is presented in appendix [Table A1].  
2.2.4  Plasma Gal-3 ELISA 
Plasma concentrations of Gal-3 were measured by ELISA in accordance with the 
manufacturer’s instructions from age sex matched WT mice fed either SD or AD. 
The commercial ELISA kit used was Gal-3 (R&D Systems- Europe Ltd. Catalogue 
number DY1197).The Gal-3 ELISA required dilution of the murine plasma samples 
with reagent buffer. The Gal-3 plasma samples were assayed in duplicate in a 96 
well plate pre-coated with the appropriate detection antibody. Plates were 
analysed immediately on a Dynex Technologies Ltd, Worthing UK MRX 2 plate 
reader and analysed with ‘Revelation’ software by Dynex Technologies. OD 
values were determined by reading the absorbance at 450 nm as the primary 
wavelength and 650 nm as the reference wavelength. Blank wells were 
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subtracted from the sample well value. Standard curves were generated by 
plotting mean absorbance against each concentration of recombinant standard. 
The concentration of protein in samples was calculated from the standard curve 
and multiplied by dilution. Inter and intra-assay Coefficient of Variation (CV) of 
the Gal-3 (and Gal-1) ELISA plates contributing to results is described in the 
appendix [Table A2, A3]. The mean CV of the Gal-3 ELISA is higher than ideal (less 
than 15%). The ability of Gal-3 to self-associate could contribute to a high degree 
of variance. Gal-3 ELISA plasma sample results with a CV greater than 20% were 
not included in this work. Plasma Gal-3 levels were raised beyond expected 
values in haemolysed plasma samples appearance, indicating a release of 
intracellular Gal-3 from disrupted cells. This was confirmed by centrifuging 
mouse blood samples at a high speed (> 800 g) [Table A4].  To reduce the chance 
of capturing intracellular Gal-3 data on ELISA any haemolysed appearance was 
documented and excluded from data analysis. Care was taken to reduce trauma 
to the integrity of the whole blood sample. Plasma sGal-3 concentrations 
included in this thesis were similar to published data [196].  
2.2.5   Real time quantitative PCR  
The details below are attempting to satisfy MIQE guidelines on minimum data 
requirements for publishing results for real time quantitative PCR (qPCR) [197].  
2.2.5.1  Total RNA isolation from solid organs  
qPCR was performed on WT murine  kidneys. Following appropriate anaesthesia 
organs were retrieved in a sterile operating field. The kidneys were retrieved by 
laparotomy. A whole kidney was ‘snap frozen’ in liquid nitrogen. The estimated 
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time from effective anaesthesia to snap freezing the kidneys was less than 2 min. 
Kidney specimens were transferred to storage at -80oC for use within 6 months. 
2.2.5.2  Nucleic acid retrieval  
Each sample was processed individually to yield mRNA in accordance with 
commercial manufacturer’s instructions (Qiagen RNeasy Mini kit: Cat no 74104). 
There were 2 techniques used for homogenising tissues in commercial buffer 
(RLT buffer).  
1- Pestle and Mortar; frozen kidneys were taken from -80oC storage into 
liquid nitrogen. A whole kidney was crushed by pestle and mortar until a fine 
powder. 30mg of powder was transferred to a 2.0 ml syringe containing 600µl of 
RLT buffer with 1% β-mercaptoethanol. The buffer and powdered tissue were 
passed through a 20-gauge (0.9 mm) needle attached to a sterile plastic 5–10 
times or until a homogeneous appearance of lysate was achieved.  
2- Ultrasonication by commercial tissue disrupter; frozen kidneys were 
taken from -80oC storage into liquid nitrogen. A whole kidney was cut into 
quarters then placed in 2 ml of RLT buffer and given 3 pulses of 30 sec with a 15 
s rest on ice to prevent overheating. This was performed until a homogenous 
appearance of lysate. Subsequent steps were identical between the 2 methods 
of tissue homogenisation. 
  
The resulting lysate was centrifuged at full speed (800g) for 3 min. Supernatant 
was pipetted into another 2 ml eppendorf™ tube and the pellet discarded. 1 
volume of 70% ethanol was added to the supernatant and mixed gently by 
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pipetting. 700µl of the ethanol/supernatant was placed in an RNeasy spin 
column in a 2 ml collection tube and centrifuged for 15 s at 10,000 rpm. The 
collected flow through was discarded. 700 µl of RW1 buffer (Qiagen RNeasy mini 
Kit) was added to the RNeasy spin column and centrifuged for 15 seconds at 
10,000 rpm. Follow through was again discarded. The spin column membrane 
was then washed by adding 500 µl of RPE buffer (Qiagen RNeasy mini kit) and 
centrifuging for 15 seconds at 10,000 rpm. The collection tube was emptied and 
a further 500 µl of RPE buffer was added to the spin column and centrifuged for 
2 min at 10,000 rpm. A new collection tube was then added to the spin column 
and centrifuged at full speed for 1 min. Finally a 1.5 ml sterile collection tube was 
placed on the spin column and 40 µl of nuclease free water was added to the 
spin column, which was then centrifuged for 1 minute at 10,000 rpm. The 
collected RNA in nuclease free water was stored at -80oC until required.  
2.2.5.3  Nucleic Acid quantity and quality assessment. 
The quality and concentration of RNA was assessed using a commercial 
spectrophotometer (Nanodrop ND-1000, NanoDrop Technologies, DE, USA). 
Nucleic acid purity was measured against a sample of genetic grade water as a 
baseline control [Table 16]. The concentration of RNA was measured in ng/µl 
from the absorbance at 260nm. 260/280 and 260/230 ratios were recorded to 
demonstrate RNA quality. The ratio of absorbance at 260 and 280 nm is used to 
assess RNA purity, and a ratio > 2.0 is accepted as pure for RNA. All samples used 
for PCR in this thesis have achieved this, however the 260/230 ratio were lower. 
The ratio of absorbance at 260 nm and 230 nm is a secondary measure of purity 
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and should be around 2. Lower 260/230 ratios could indicate the presence of a 
contaminant absorbing at 230. Possible contaminants include carbohydrates, 
phenols and EDTA. The RNeasy Mini kit does not contain phenolic compounds. A 
260/230 ratio of >1.8 is generally acceptable. Genomic DNA contamination is 
claimed unlikely using RNeasy spin since the silica-gel–membrane, spin-column 
technology efficiently removes the majority of the DNA without DNase 
treatment. However a DNase step in reverse transcriptase would reveal possible 
contamination. 
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Table 16: RNA quality and quantity assessment of kidney specimens used for PCR 
in this thesis. 
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2.2.5.4  cDNA synthesis. 
RNA was quantified and equilibrated for all samples to 1000ng total per sample 
to be reverse transcribed into cDNA. The following steps followed 
manufacturer’s instructions for Superscript (II) Reverse transcriptase by 
Invitrogen (Cat no 18064-014).To a nuclease-free microcentrifuge tube the 
following were added; 1µl of random primers, 1 µl dNTP Mix [10mM], RNA 
volume (variable to equilibrate) and genetic grade water to make up the volume 
to 12 µl.  The samples were then placed in a G-Storm thermal cycler and the 
contents heated to 65o C for 5 min. Samples were removed, chilled on ice and 
then briefly centrifuged. The following was then added to each microcentrifuge 
tube; 4µl of 5x First-Strand buffer, 2µl of DTT (0.1M) and 1µl of RNaseOUT to a 
total volume of 19 µl per sample. The samples were placed back in the G-storm 
thermic cycler and incubated at 25oC for 2 min. At this point the heating cycle 
was paused, the lid of the cycler was opened and 1 µl of Superscript 2 Reverse 
Transcriptase was added to each tube and mixed by gently pipetting up and 
down. The cycler lid was then closed and the 25oC program continued for 10 
min, 42 oC for 50 min and finally the samples were inactivated by heating to 70 
0C for 15 min. This yielded a 20µl volume to which 80µl of nuclease free water 
was added. The resulting cDNA samples were then stored at -80 oC until ready to 
be used for qPCR. 
2.2.5.5  Real Time Quantitative PCR 
qPCR was performed with Absolute qPCR Mix (AB-1139). A mastermix was 
generated for each gene of interest. 10 µl samples were manually pipetted in 
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0.1ml Corbett style strip tubes. The house keeper gene was 18s (TaqMan® 
Ribosomal RNA Control Reagents - catalogue number 4308329), the probe was 
conjugated to a VIC fluorophores designed to detect ribosomal 18s RNA. The 
probe on the Gal-3 probe was FAM (6-carboxyfluorescein). Both fluorophores 
are TaqMan™ probes with VIC being detected on the yellow channel and FAM on 
the green channel of the Corbett 6000 thermal cycler. All samples were 
performed at least in duplicate. Once prepared the samples were placed in the 
Corbett 6000 thermal cycler and the following thermal cycling profile used.  
Samples were held before cycling at 50oC for 2 min then 95oC for 10 min before 
undergoing 50 cycles of 95oC for 15 sec and 60oC for 60 s.  
 
2.2.5.6  Primers and Probes 
Gene of interest Primers and Probes were purchased from Sigma-Aldrich and 
sequences shown below. All primers and probes were stored at -20oC.  For qPCR 
they were diluted to 100µM. Primers were used at 500nM and Probes at 250 
nM. 
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Table 17: qPCR target genes of interest used during this thesis showing gene 
names, chromosome and gene accession number. Chapter 2 gives results for 
Gal-3 and CD 68 PCR data. Data from fibrosis genes (Pro-collagen (1), TGF-β, α-
SMA) and Macrophage subset differentiation genes (CHI-313 and Retnla) are 
presented in Chapter 3 of this thesis. 
 
 
Table 18: Commercial Primer / probe sequences purchased from Sigma Aldrich. 
Commercial primers and probes purchased from Sigma-Aldrich, TaqMan probes 
were used exclusively for PCR.  
  
92 
 
2.2.5.8  Agarose gel of amplicons from qPCR 
Agarose gel electrophoresis of products from the housekeeper (18S), α-SMA, 
TGF-β, Procollagen (1) and Gal-3 PCR was performed to exclude contaminants in 
the amplification process. All genes showed a single band excluding significant 
RNA contamination in the amplification process [Fig 2]. Agarose gels for CD-68, 
CHI-313 and Retnla genes were not performed due to time constraints. 
2.2.5.8.1  Agarose gel methodology 
Agarose gel electrophoresis was performed by Julius Kieswich.  10µl volumes 
from qPCR reactions were mixed with commercial gel loading buffer (Sigma Cat 
no: G2526) and separated on 2% agarose gel. The gel was then stained with Gel 
Red (Cambridge Biotechnology Cat no: BT41003) for 30 min before 
photographing over an Ultra-Violet (UV) light (UVIP).  
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Figure 2: Gel of housekeeper (18s), α-SMA, TGF-β and Procollagen (1) amplicons 
after qPCR. There is a single band for each gene at the appropriate amplicon 
length for the 18s housekeeper and genes of interest. Amplicon length of 18s = 
187bp, α-SMA = 68 bp, TGF-β = 72bp and Procollagen (1) amplicon = 65 bp. 
There are no differences between lanes because this is taken after 40 cycles at 
the linear phase of amplification.  
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2.2.5. qPCR Data analysis 
qPCR was performed in the investigators laboratory and data interpreted by the 
investigator. Comparative quantitation was used to compare data and unlike the 
delta-delta CT method this does not require assessment of reaction efficiencies 
before analysis. Analysis was conducted on the Corbett 6000 software and 
exported to Microsoft Excel. Only data with low standard deviation between 
samples (<0.7) were included in results. For analysis no template controls (NTC) 
and reverse transcriptase controls (RTC) were switched off. Samples were 
performed at least in duplicate and preferably in triplicate. Because TaqMan™ 
primers and probes were used melt curve analysis could not be performed. 
2.2.6  Leucocyte Fluorescence-Activated Cell Sorting 
2.2.6.1  Fluorescence-Activated Cell Sorting (FACS) analysis of circulating 
leucocytes 
WT and Gal-3 -/- fed SD or AD had FACS analysis of their circulating leucocytes 
from whole blood samples obtained after anaesthesia. Mice were underwent 
cardiac puncture to obtain approximately 200-500 µl of whole blood into a 
heparinised syringe. Erythrocytes were lysed using 10 mL 1x lysis buffer per 
blood sample (RBC lysis Buffer 10x, eBioscience, Cat no: 00-4300-54). The sample 
was agitated for 30 s until clear. 5 mL of ice-cold PBS was then added to each 
sample to halt lysis. Samples were centrifuged at room temperature at 300 g for 
10 min. The supernatant of lysis buffer and lysed erythrocytes was discarded and 
the cell pellet of leucocytes was suspended in 100 µL of Phosphate Buffered 
Saline (PBS) +0.1% Bovine Serum Albumin (BSA). The cell suspension was plated 
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onto a 96 well plate and washed twice with 100 µL of PBS (+0.1% BSA). The 
washing step involved adding 100 µL of PBS (0.1% BSA) to each well, centrifuging 
at 1000 rpm at 4oC for 8 min then discarding the supernatant and repeating the 
step. Care was taken to agitate the cell pellet during the washing by pipetting up 
and down to adequately wash the cells. Suspended cells were then incubated for 
10 min with FC block (anti-mouse CD16/CD32) on ice in the dark [Table 19]. 2 
wash steps were repeated and the cells were incubated with cell surface 
antibodies on ice in the dark for 30 min. The cells were then washed twice again 
then fixed by adding 100 µL of fixation buffer per well and samples were 
incubated at room temperature for 20 min in the dark (IC Fixation Buffer, 
eBioscience, Cat no: 00-8222-49). Following fixation 200 µL of permeablisation 
buffer (PB) was added to each well and then washed twice more in PB 
(Permeablisation Buffer 10x, eBioscience, Cat no: 00-8333-56). The cells were 
then incubated at 4oC in the dark for 45 min with intracellular antibody or 
isotype control in PB. Following incubation cells were washed 2 more times in PB 
and left in 100 µL of pure PBS. Samples were kept on ice in the dark until 
analysis. 
2.2.6.2  FACS analysis of peritoneal macrophages 
WT mice fed SD and AD were used for FACS analysis of resting peritoneal 
macrophages. The peritoneum was not inflamed prior to analysis which has been 
described in WT and Gal-3 -/- mice previously. In contrast to harvesting whole 
blood, mice were not anaesthetised by IP injection of X/K but underwent cervical 
dislocation to minimise peritoneal trauma and inflammation prior to analysis. 
After cervical dislocation 5 mL of peritoneal lavage solution (PBS + 0.25% BSA 
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and 2 mM Ethylenediaminetetraacetic acid EDTA) was injected into the 
peritoneal cavity. The abdomen was gently manipulated for 2 min. After 2 min 
the lavage solution was aspirated from the peritoneal cavity into a 5 mL syringe. 
An erythrocyte lysis step was not undertaken and following this all steps were 
performed as outlined in section 2.2.6.1. 
 
2.2.6.3 Flow Cytometry controls and data analysis. 
CD 11B, Gal-3, Ly6c were optimised at different concentrations to use the 
minimum concentration necessary to achieve acceptable results [Fig 4]. All 
antibodies were used in conjunction with isotype controls at the same 
concentration. An isotype control is a flourochrome of the same antibody class 
as the primary conjugated antibody but lacks the binding epitope. Isotype 
controls demonstrate how much non-specific binding there is. Unstained 
controls were also used in conjunction with isotype controls to discern a true 
fluorescent effect above baseline. 
All samples were analysed on the same Beckton-Dickinson fluorescence 
activated cell sorter (FacsCalibur A). Voltage and compensation parameters were 
set for each experiment to achieve the optimum reading of sample against its 
isotype. All FACS data were analysed using Flo-JoTM software (version 7.6.5). 
Leucocyte sub-populations were gated by a combination of size (forward scatter 
– fsc), granularity (side scatter – ssc) and positivity for cell-markers CD11b and 
Ly6c (monocytes) ly6g (granulocytes) and CD-68 (macrophages). Compared to SD 
fed WT leucocytes after 3 weeks of diet, AD fed WT leucocytes showed increased 
auto-fluorescence, and increased susceptibility to permeabilisation – which 
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reduces side scatter characteristics. The data had to be analysed taking this into 
account. The use of an isotype controls reduced concern over the contribution of 
auto-fluorescence to the final results [Fig 3, Table 19]. 
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Figure 3: Optimisation of antibody concentrations used in flow cytometry. All 
antibodies used in flow cytometry were fluorochrome conjugated primary 
antibodies. Each antibody was assessed against an unstained sample and isotype 
control. Different concentrations of antibodies were tested to give an optimal 
fluorescence separation from its isotype control. Panels show unstained sample 
(orange line), isotype control (blue line) and primary fluorochrome associated 
antibody (red line). 
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Table 19: Commercial antibodies used in FACS of murine whole blood in this 
thesis. 
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2.2.7 Histopathology 
All samples collected for histology were washed briefly in 0.9% normal saline, 
and then placed in 10% formalin for 48 h. After this they were placed in 70% 
ethanol before being embedded in paraffin. Histology was performed by the 
William Harvey institute Cancer Pathology services. Briefly 4 µm thick tissue 
sections were cut from organs mounted on paraffin blocks.  Histological scoring 
was by performed by myself blinded to the treatment of the animal and scoring 
randomly assessed and agreed with a Consultant Histopathologist, Professor 
Sheaff, using ImageJ software. 
2.2.7.1  Renal Gal-3 immunohistochemistry 
The primary anti-Gal-3 antibody was optimised to a 1:250 dilution using mouse 
lung as a positive control (Goat anti-mouse Gal-3, R+D systems, Cat no: BAF1197) 
[Fig 4]. Secondary HRP conjugated antibody was a polyclonal rabbit anti-goat 
biotinylated used at a dilution of 1:100 (Rabbit anti-goat, Dako, Cat no: E0466). 
Non-specific secondary antibody staining was assessed by using secondary 
antibody incubation alone without primary antibody.  
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Figure 4: Immunohistochemistry, Gal-3 antibody optimisation using mouse lung 
as a positive control. Gal-3 was optimised to a dilution of 1:250 which eliminated 
the majority of background non-specific immunoperoxidase staining. 
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2.2.7.2 Macrophage (F4/80) immunohistochemistry 
4µm kidney sections were stained with a rat anti-mouse F4/80 primary antibody 
(F4/80, IgG2b T-2008, BMA Biomedicals) at 1:100 dilutions. An isotype control 
(ABD Serotec IgG2b Negative Control -MCA1125) was also used to demonstrate 
non-specific staining at the same dilution.  
2.2.7.3 Histopathological scoring 
The number of F4/80 +ve cells per x40 field was used to quantify renal interstitial 
macrophage number. 6 x40 cortical images were used per animal. The mean 
number of cells per image was calculated and compared between groups [Figure 
5]. 
 
Figure 5: Histological F4/80 positive cell scoring of x 40 magnification image of 
mouse renal cortex. A x40 image was divided into 6 areas and F4/80 +ve cells 
marked with a black line. The cells were counted per square then added to get 
an overall number of F4/80 +ve cells per x40 image. 6 images per cortex were 
scored for each animal and a mean of the numbers of cell was generated per 
animal. 
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2.3 Results 
2.3.1  Characterisation of optimum duration of AD-CKD in mice. 
AD diet induces renal failure and weight loss in WT mice 
7 week old WT mice were allocated to SD or AD and harvested at 1, 2, 3 and 4 
weeks duration of diet. Body weight and plasma Cr was measured in each animal 
at weekly intervals [Table 20].  AD fed mice had increased mean plasma Cr at 1 
week of diet compared to SD mice at 1 week. After 2 weeks of AD the Cr rose 
significantly compared to SD mice, indicating significant kidney impairment. AD 
fed mice continued to develop progressive uraemia over the 3rd and 4th week. 
Mortality was high at the 4th week and optimal duration of diet was felt to be 3 
weeks for subsequent experiments.  10 week old WT mice harvested at 3 weeks 
demonstrated similar plasma Cr differences between AD and SD fed mice and 
tolerated the diet better [Fig 7]. For all subsequent AD experiments 7 week old 
mice were used for 3 week duration to maximise efficiency and reduce expense. 
2.3.1.1 Determination of optimum age of AD-CKD mice 
WT mice lose weight over 4 weeks of AD. 
WT AD fed mice rapidly lose body weight over the 4 weeks [Table 20, Fig 6a]. At 
4 weeks there was a significant mortality with just under 25% of mice dying in 
the last week (data not shown). The second experimental group had less weight 
loss comparatively to the first group but a similar mortality. The 7 week old WT 
mice were not weighed each week, only at harvest, so mean weight over time 
does not reflect weights from the same individuals. Data of weight changes 
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within the same group of 10 week old WT mice fed AD or SD was subsequently 
collected [Fig 6b]. Collecting data sequentially on the same group of individuals 
rather than different individuals each week demonstrated a more consistent 
weight loss with a lower mean weight each week [Fig 6b]. 10 week old WT 
animals were heavier than the 7 week old animals and had a lower mortality at 4 
weeks. The amount of diet consumed by 10 week old animals was assessed by 
distributing a set weight of both SD and AD to each cage every week. Before the 
next food refill the remaining feed was re-weighed and the total weight of diet 
consumed was recorded. This remained constant over time and equivalent 
between the WT SD and AD fed mice (Chapter 3, section 3.3.1). The AD is 
pelleted and SD expanded so it is possible the pelleted diet, being smaller, could 
fall between food trough bars, not consumed.  The implication being that AD 
could fall into the cage without being consumed so the weight of leftover AD 
would not therefore indirectly correlate with consumed AD feed. 
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Table 20: Plasma Cr and body weight data for 7 week old WT mice fed SD or AD 
diet over 4 weeks. Plasma Cr and body weights are shown as mean (± standard 
deviations) values. At 1 week SD vs AD there is a significant increase in mean 
plasma Cr in the AD group, p= 0.071 (unpaired t-test). The mean plasma Cr 
continues to increase over the duration of diet whilst SD fed mice have no 
statistical increase in their plasma cr. Body weight also falls significantly at 1 
week AD compared to SD fed mice, p=0.0012 (unpaired t-test).This table refers 
to WT animals only. At 4 weeks AD animals had significant mortality and body 
weight lost. Further experiments used mice fed AD for 3 weeks only for better 
survival and subsequently greater consistency of data. 
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Figure 6: Body weight data Mean (SEM) from 2 different age groups of WT mice 
fed AD or SD over 4 weeks. (a) Body weights from 7 week old mice. SD fed mice 
body weight is significantly greater than AD fed mice from 1 week diet p=0.0356 
(Mann Whitney). (b) Body weights of 10 week old mice again show a significant 
difference in weights between SD fed mice and Ad fed mice from 1 week diet 
p=0.0317 (Mann Whitney) 
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Figure 7: Plasma Cr at 3 weeks AD diet in different age groups of mice.  (a)  
Scatter plot of plasma Cr with individual results amongst groups with error bars 
displaying mean and standard deviation values (b) Mean (Standard Deviation) 
values of plasma Cr data from 7 week old vs 10 week old WT mice taken at 3 
weeks of AD. Plasma Cr was not significantly different (NS) between the 7 week 
old AD fed WT vs 10 week old AD fed WT mouse groups, Cr = 55.28 µmol/L (±17) 
vs. 61.04 µmol/L (± 18.49) p=0.53.  
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2.3.2 Soluble Gal-3 in experimental uraemia 
2.3.2.1  Plasma sGal-3 concentration is elevated from 1 week in AD 
treated WT mice. 
47 WT mice o were used to assess sGal-3. Plasma sGal-3 was measured by ELISA 
in duplicates. 25 mice were assigned to SD (10 had sGal-3 measured at 1 week 
diet, 8 measured at 2 weeks SD and 7 measured at 3 weeks). 22 mice were used 
in the AD group (10 had sGal-3 measured at 1 week AD, 7 mice had sGal-3 
measured at 2 weeks AD and 5 mice at 3 weeks AD). The lower numbers in the 
week 3 AD reflecting the significant mortality at this point. Of those 47 
measurements only 16 SD fed mice and 16 AD fed mice had duplicate plasma 
sGal-3 values with a CV < 20%. Any sample with a duplicate CV > 20% was 
excluded from analysis.  
Plasma sGal-3 rose within a week of commencing the AD, compared to SD fed 
mice (19.05 vs 16.24 ng/ml) [Fig 8a]. This reached statistical significance after 3 
weeks of diet and there is a significant positive correlation between plasma Gal-3 
and plasma Cr [Fig 8b]. sGal-3 levels are equivalent to concentrations seen in 
pathological human disease including CKD.[138]  The sGal-3 increases in the AD 
only reached significance at 3 weeks so it was decided to examine Gal-3 
expression in circulating leucocytes at this time point on the diet.  
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Figure 8:  sGal-3 in the AD over time in WT mice. (a)Plasma sGal-3 ELISA over 3 
weeks SD or AD in 7 -10 week old WT mice. Table shows median sGal-3 values 
(standard deviation). Median plasma Gal-3 rose in a time dependent manner in 
AD fed animals. This only reaches significance at 3 weeks AD, p=0.0095 (Mann 
Whitney U). Though SD fed mice have a reducing median plasma sGal-3 over 3 
weeks this does not reach statistical significance. (b) Linear regression of plasma 
Cr vs plasma sGal-3 in 32 WT mice fed either SD or AD. Line shows best fit with 
dashed lines the 95% confidence intervals. There is a significant positive 
correlation between plasma Cr and sGal-3 with Pearson’s r = 0.55, p=0.0012. 
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2.3.3 Circulating leucocyte Gal-3 expression in the AD 
2.3.3.1  Circulating monocyte Gal-3 expression is increased at 3 weeks 
AD. 
12 WT mice were used to analyse circulating monocyte Gal-3 staining by flow 
cytometry. 5 mice were placed on SD for 3 weeks, 5 mice were given 1 week of 
AD and 5 mice given 3 weeks of AD. Only 2 of the SD fed mice had suitable 
processing for FACS analysis. The 1 week AD animals were an important control. 
At 1 week of AD we had determined that plasma Cr was not significantly 
elevated from SD fed mice, that body weight was not significantly and that 
plasma sGal-3 was not significantly different from SD fed animals. Therefore the 
1 week AD fed group would enable us to see if there was a direct adenine effect 
on monocytes independent of uraemia and weight loss that would come with a 
longer dietary duration. Because the SD number was low and plasma Cr, body 
weight and plasma sGal-3 were not significantly different between SD fed mice 
and 1 week AD the FACS results for both these controls were grouped together 
to enable appropriate statistical comparison 
All mice were harvested on the same day for flow cytometry. Permeablised 
monocytes were gated from live events by size and granularity characteristics 
(ssc/fsc) and positivity to the monocyte marker Ly6c [Fig 9 a+b]. The median Gal-
3 MFI and % of events gated as monocytes were recorded per animal. Mice fed 
an AD had equivalent numbers of monocytes but there was significant 
monocytosis evident at 3 weeks of AD feeding [Fig 9c]. A median 25.65% (±2.19) 
of the total events were gated as monocytes in the SD fed mice, 19.9% (±2.45) in 
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the 1 week AD fed mice and 48.2% (±9.87) in the 3 weeks AD group [Table 21]. 
Of those gated monocytes Gal-3 Median Fluorescence Intensity (MFI) was 
significantly greater in 3 week AD fed mice compared to both SD fed mice and 1 
week AD fed mice, 797.4 (±36.84) vs 519.5 (±68.5) and 402.6 (±24.42) 
respectively [Table 21]. 
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Figure 9: Circulating monocyte gating and Gal-3 expression in cells isolated from 
animals fed with an AD compared to those on a SD. Cells with side scatter and 
forward scatter characteristics compatible with monocytes are sorted (a). (b) 
Cells within this grouping (based on size and granularity) had the monocyte 
marker (ly6C) median fluorescence intensity measured to select monocytes. (c) 
Gal-3 MFI and cell count from a representative WT mouse fed SD (red line) 
compared to a WT mouse fed 3 weeks SD (black line ). This demonstrates the 
marked monocytosis that adenine fed animals develop at 3 weeks AD and 
increased Gal-3 expression by MFI (a Gal-3 isotype control is shown by a filled in 
black histogram).  
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Table 21: FACS analysis of monocyte proportion of gated event and monocyte 
Gal-3 expression (as median fluorescence activity (MFI)).  (a) Median Gal-3 MFI 
and % events gated as monocytes increases at 3 weeks but not 1 week of AD in 
WT mice compared to SD fed WT mice. (b) The SD and 1 Wk. AD fed mice are 
control groups with equivalent Cr, body weight, plasma sGAl-3, % monocyte 
proportion and monocyte Gal-3 MFI. The 2 control groups were combined to test 
for statistical significance. The 3 Wk. AD fed group had a significantly greater 
proportion of gated events identified as monocytes and a significant increase in 
monocyte Gal-3 expression (Mann Whitney).  
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2.3.4 Solid Organ Gal-3 expression in the AD fed mice 
2.3.4.1  Renal but not cardiac, lung, or aortic Gal-3 is elevated at 3 weeks 
AD.  
Solid organs (heart, aorta, lung and both kidneys) were harvested from 5 mice 
fed SD for 3 weeks and 5 mice fed AD for 3 weeks. The organs were snap frozen 
then homogenised and assayed for protein content and Gal-3 content on ELISA. 
Only one kidney from each animal was used for Gal-3 ELISA, the contralateral 
kidney was harvested for immunohistochemistry. Gal-3 ELISA was performed in 
duplicates and where duplicates had a CV > 20% they were excluded for analysis. 
Kidney homogenate data had 2 samples excluded because of excessive CV 
values. There were no significant differences in Gal-3 values after 3 weeks AD or 
SD for heart, lung or aortic tissue homogenate [Table 22]. As previously 
documented lung Gal-3 content is very high (38.2 ng/mg tissue) and is often used 
as a positive control in immunohistochemistry. The aortic Gal-3 level was higher 
than expected (10.82 and 10.61 ng/mg tissue). This is likely because of the very 
low levels of protein measured from the aortic samples. Cardiac Gal-3 is not 
elevated on tissue ELISA which was validated on Gal-3 immunohistochemistry 
[Appendix]. The only organ assayed to show a significant increase in Gal-3 
expression after feeding an AD was the kidney [Table 22].  There is a concern 
that the SD fed kidney Gal-3 value is unexpectedly low since murine kidneys 
express Gal-3 in distal convoluted tubular epithelium and transitional cell 
epithelium. However an increase in kidney Gal-3 at 3 weeks of AD compared to 
SD is further validated by immunohistochemical and PCR data [Fig 10 +11]. 
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Table 22: Summary table of Gal-3 content of different solid organs in 7 week old 
WT mice after 3 weeks AD by ELISA. Murine tissue was homogenised and a BCA 
assay performed to assess protein content of the samples. Tissue homogenate in 
buffer was then subject to commercial murine Gal-3 ELISA. The Gal-3 value from 
ELISA was divided by the protein concentration of the tissue sample to correct 
for discrepancies in amount of tissue present. All Gal-3 samples were performed 
in duplicate and where the CV of duplicates exceeded 20% the sample was not 
included in the results. * Kidney homogenate median Gal-3 corrected for protein 
content of tissue in SD = 0.38 ng/mg (±0.11) vs AD mean Gal-3 of 3.44 ng/mg 
(±0.54) p= 0.016 (Mann Whitney). 
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2.3.4.2  Renal cortical and medullary Gal-3 is increased in tubular 
epithelial cells and interstitial cells at 3 weeks AD. 
3 kidneys from SD fed mice and 5 kidneys from AD fed mice were processed for 
immunohistochemistry using a Gal-3 primary antibody. Morphometric analysis of 
the Gal-3 immunoperoxidase positive area was performed on 6 x cortical and 6 x 
medullary images (x40 magnification images) per animal. The mean % area 
quantified as Gal-3 positive was recorded and compared between SD and AD fed 
mice. The immunoperoxidase stain demonstrated an increase in Gal-3 
expression in renal tubular epithelial cells and Gal-3 positive infiltrating 
leucocytes [Fig 10a].  Medullary and cortical Gal-3 expression measured as % 
area positive for Gal-3 was significantly elevated [Fig 10b]. 
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Figure 10: Renal gal-3 expression on immunohistochemistry in WT mice fed AD 
or SD. x40 image of renal cortex with anti-Gal-3 primary antibody and secondary 
immunoperoxidase stain. (a) Representative x40 images of renal cortex in SD and 
AD fed mice. Renal tubular epithelial expression of Gal-3 is limited to collecting 
duct epithelia, and distal convoluted tubule in SD fed WT mice. AD fed mice 
develop Gal-3 positive cell infiltrates and increased Gal-3 expression in tubular 
epithelium. (b) Quantitative assessment of mean Gal-3 +ve area of x40 images (6 
per mouse) showing significant increase in x40 image area +ve for Gal-3 by 
morphometric analysis p = 0.036 (Mann Whitney). SD = 3 mice AD = 5 mice 
 
118 
 
2.3.4.3  Gal-3 gene expression is significantly increased at 3 weeks AD. 
qPCR analysis of Gal-3 gene expression was undertaken from the kidneys of 5 
mice fed SD for 3 weeks and 6 fed AD for 3 weeks. RNA was extracted from the 
kidneys and qPCR was performed using a Gal-3 primer and probe and 18s as a 
housekeeper gene. Comparative quantitation analysis showed all 6 AD fed mice 
had a higher Gal-3 gene expression compared to SD fed mice [Fig 11]. 
 
 
Figure 11: Quantitative real time PCR of 10 week old WT SD and AD kidney 
homogenate for Gal-3 mRNA. Results of comparative quantitation analysis of WT 
SD and WT AD Gal-3 mRNA divided by a 18s housekeeper gene. Relative 
expression of WT AD compared to WT SD using the WT SD as a calibrator gene 
with an expression of 1. * Relative expression of Gal-3 mRNA/18s housekeeper in 
WT SD vs WT AD 1.58 (±0.91) vs 6.82 (±2.3) p= 0.0135 Mann-Whitney 
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2.3.5 Renal and Peritoneal macrophage in the AD 
2.3.5.1  Renal interstitial macrophage (F4/80) numbers are elevated in 
WT Kidneys in mice fed AD at 3 weeks compared to SD fed controls. 
7 week old WT mice fed SD or AD for 3 weeks were harvested and kidneys 
processed for immunohistochemistry using an F4/80 primary antibody and HRP 
conjugated secondary antibody. 6 images of renal cortex per animal were taken 
(x40 magnification). The number of F4/80 cells was counted per x40 image and 
averaged per animal. The median values were then compared between SD and 
AD fed mice. The quality of staining meant that only 2 SD and 3 AD fed mice 
were included. All AD fed mice had greater numbers of F4/80 positive cells 
(representing macrophages), median 113.5 (±38.42) F4/80 +ve cells vs 35.84 
(±3.3) [Fig 12a +b]. The lack of SD numbers meant statistical significance could 
not be tested.  
2.3.5.2  Renal CD-68 (Macrophage) relative gene expression is 
significantly elevated in the AD. 
Kidneys from 5 SD fed WT mice and 6 AD fed mice aged 10 weeks were 
harvested and had RNA extracted for qPCR using a CD-68 primer and probe and 
18s housekeeper. Comparative Quantitation analysis of relative gene expression 
using a SD fed kidney as a calibrator gene demonstrated a significant increase in 
CD-68 gene expression in AD fed mice 2.25 (±0.66) vs 1.0 (±0.02) p=0.0067 
(Mann Whitney) [Fig 12c].   
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Figure 12: Renal interstitial macrophages at 3 weeks AD vs 3 weeks SD in WT 
mice by immunohistochemistry and qPCR. 6 slides of renal cortex per mouse 
were scored for numbers of F4/80 cells. (a) Bar chart of median and range of 
mean numbers of cells per animal. WT AD fed mice (n=3) at 3 weeks had greater 
numbers of F4/80 positive cells than WT SD fed mice (n=2), median number of 
F4/80 +ve cells per slide = SD- 35.84 (± 3.3) vs AD 113.5 (± 38.42). (b) 
Representative x40 images of renal cortex from WT mice fed AD (top) and SD 
(bottom). (c) bar chart showing median and range of CD-68 relative gene 
expression by qPCR from kidney homogenate of WT mice fed SD or AD for 3 
weeks.CD-68 expression was significantly higher in AD fed mice 2.25 (± 0.66) vs 
1.0 (± 0.02), p=0.0067 (Mann-Whitney). 
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2.2.5.2  Peritoneal macrophage numbers and Gal-3 expression are 
equivalent at 3 weeks AD compared to SD fed WT mice. 
To assess whether Gal-3 expression was increased in a macrophage population 
remote from the kidneys peritoneal macrophages were isolated. This experiment 
again used SD fed mice and 1 week AD fed mice as controls. 5 mice were fed SD, 
5 were fed AD for 1 week and 5 were fed AD for 3 weeks. All mice were 
harvested on the same day. Peritoneal lavage and aspirate was performed and 
cells within the aspirate analysed by flow cytometry. Macrophages were defined 
(gated) by SSC and CD-68 positivity [Fig 13 a +b]. The percentage of macrophages 
from the total number of events was equivalent in all 3 groups [Fig 13 c + d]. Gal-
3 MFI of the defined macrophages was also equivalent between SD fed mice and 
AD fed mice at 1 and 3 weeks [Fig 13 c+d]. 
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Figure 13: FACS data for Gal-3 expression of peritoneal macrophages in WT mice 
fed SD and AD at 1 and 3 weeks. Gating of macrophages from peritoneal 
aspiration (a) shows forward and side scatter, (b) macrophages are identified by 
side scatter characteristics and positivity for CD 68 (Fl-1 flourochrome)(c) 
Representative FACS histogram, WT peritoneal aspirate demonstrates equivalent 
numbers of macrophages and permeablised Gal-3 (fl-2) MFI at 1 and 3 weeks of 
AD compared with SD fed mice at 3 weeks. The solid black histogram is an Fl-2 
isotype control, red histogram = SD fed mouse, blue histogram = 3 week AD fed 
mouse, black histogram = 1 week AD fed mouse. (d) Krushkal Wallis one way 
analysis of variance demonstrates no significant difference in median Gal-3 MFI 
between groups or the percentage of gated events that are defined as 
macrophages by SSC and CD-68 positivity (p=0.1479, p=0.8781 respectively). 
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2.4. Discussion 
2.4.1 Elevated sGal-3, monocyte Gal-3 and renal Gal-3 in the AD. 
sGal-3 is elevated in the AD model of experimental uraemia and renal fibrosis in 
a time dependent manner reaching significance at 3 weeks. The cause of 
elevated sGal-3 in murine plasma is not known. Gopel et al. hypothesised 
elevated sGal-3 in human CKD could be as a result of reduced renal clearance or 
increased production.[138] Gal-3 is detected in the urine, however the expression 
of Gal-3 on transitional cell epithelium means that measured urinary Gal-3 is not 
necessarily filtered through the glomerulus but may be from a source lower in 
the urinary tract. The main clearance of sGal-3 is thought to be hepatic.[49, 50] We 
attempted to measure urinary Gal-3 in WT mice fed AD compared to SD over 3 
weeks but the ELISA proved difficult to perform on urine specimens with large 
standard deviations and coefficient of variations in measured Gal-3 [Appendix 
Table]. A plausible cause of elevated sGal-3 in the AD is secreted Gal-3 from 
monocytes. Monocytes and macrophages have the highest leucocyte expression 
of Gal-3 and monocytes are the only documented leucocyte to secrete Gal-3.[70, 
71]  
FACS analysis of monocytes subjected to the AD demonstrated a significant 
circulating monocytosis at 3 weeks of diet compared to controls. Similar levels of 
monocytosis have also been demonstrated in the UUO model which suggests the 
monocytosis may be independent of uraemia. Our data demonstrated a 
significant increase in Gal-3 expression of monocytes at 3 weeks of AD compared 
to controls. The monocytes were permeablised so this is a total Gal-3 expression 
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rather than cell surface specific expression.  Tissue resident macrophages in the 
non-inflamed peritoneum did not demonstrate any increase in numbers or Gal-3 
expression. This may be due to the relative protection of the peritoneum from 
the uremic milieu. Other organs, the heart, lungs and aorta did not demonstrate 
increased Gal-3 expression on ELISA. The only solid organ to demonstrate 
significant increased Gal-3 expression was the kidney. In the AD the kidney is the 
focus of inflammation. Immunohistochemistry suggested that Gal-3 expression 
was not only due to an increase in the expression of tubular epithelial cells but 
also there was the presence of interstitial Gal-3 in infiltrating leucocytes. 
Unfortunately dual staining was not performed but these are likely to be 
infiltrating cells of monocyte / macrophage lineage. WT AD fed mice at 3 weeks 
did have more F4/80 positive cells in renal cortex and a significantly elevated CD-
68 expression on qPCR. These data indicate a source of elevated sGal-3 could be 
monocyte derived, that renal infiltrating monocytes and macrophages are also a 
source of Gal-3 which could potentiates the interstitial fibrosis seen in the AD. 
Gal-3 is known to facilitate leucocyte-endothelial attachment and 
transmigration. A hypothesis generated from my data is that elevated sGal-3 and 
monocyte Gal-3 facilitates renal monocyte transmigration from blood to renal 
interstitium. Increased monocyte transmigration leads to increased renal 
interstitial macrophage numbers and renal fibrosis via macrophage– fibroblast 
interactions. Chapter 3 will examine this hypothesis by performing the AD in a 
constitutive Gal-3 -/- mouse. 
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2.4.1 AD model as a comparator to human CKD 
The protocol for AD used in this thesis is too short (4 weeks) to demonstrate 
some of the pathologies of CKD. The 4 week AD should be regarded as a 
subacute model and is more relevant to the study of a human tubulointerstitial 
nephritis mechanism rather than a true CKD model. The weight loss 
demonstrated by mice fed 0.25% AD is a significant confounding factor to 
interpretation of the results. Mice have an aversion to eating AD and a model of 
starvation is unethical and unhelpful when considering human CKD. To gain 
reassurance that the mice were consuming the AD I weighed the diet used over a 
week which was equivalent to mice fed SD and AD. The AD is pelleted, however, 
which is more compact and smaller than the expanded SD. Thus the AD would be 
more likely to fall between the bars of the food cage and I can’t confirm a 
reduction in diet mass weighed at the end of a week directly corresponded to 
diet consumed. Gavage was considered but murine adenine gavage has a high 
mortality and is not recommended.[192] The severity of weight loss meant there 
was a high mortality at the end of 4 weeks of AD of approximately 25%. Results 
in the 4th week of diet were more variable and the mice frail which made 
anaesthesia and cardiac puncture difficult as well as giving a reduced amount of 
plasma for analysis. For these reasons it was decided to analyse further work on 
mice at 3 weeks of diet when mortality was reduced and when a better blood 
volume for analysis could be achieved. This was particularly important for whole 
blood flow cytometry, which relies on good yields. Whilst analysing mice at 3 
weeks of 0.25% AD reduced the morbidity and mortality, it further reduces the 
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application of this model to human CKD. In future the 8 week AD protocol using 
a casein chow mixture should be applied but this protocol was not available until 
2013 and was not on our group Home Office licence. WT week 3 AD mouse has a 
reduced body weight, is polyuric and normotensive which contrasts significantly 
from overweight, hypertensive patients which have become the norm in human 
advanced CKD.  
2.4.2 AD as a reliable model of subacute uraemia and tubulointerstitial 
nephritis 
All mice used and fed AD demonstrated weight loss, elevated creatinine and 
renal histological changes of tubulointerstitial nephritis. In WT mice a reduction 
in body weight and elevated creatinine could be seen after 1 week AD in all 
animals. Weight loss and elevation in Cr persisted reliably until 3 weeks of AD, in 
the final week results were more variable.  
2.4.3 Measuring renal function in the AD 
Serum creatinine and blood urea nitrogen reflect glomerular filtration rate (GFR) 
poorly in mild and moderate renal impairment.[198] Serum Cystatin-C is the gold 
standard for measuring underlying GFR in mouse experiments but unavailable to 
use in these experiments. Cystatin-C is more accurate than creatinine and shows 
earlier GFR impairment than serum urea in murine I/R and 5/6nx than serum 
creatinine.[199] In this thesis plasma creatinine was used as a measure to infer 
changes in GFR. Cr is influenced by GFR but also muscle bulk which is reduced in 
3 week AD fed mice. The observation of reduced muscle bulk is subjective by my 
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inspection on laparotomy and thoracotomy. Therefore, it may be plasma Cr is an 
underestimate of the reduction in GFR that mice fed AD demonstrate. Whilst the 
plasma Cr can be used as an indicator of GFR, it should be interpreted with 
caution. The use of histological assessment of kidneys in conjunction with an 
appreciation of plasma creatinine allows a more confident comparison of renal 
impairment between groups of mice. Cr divided by body weight has been 
advocated as more reliable than Cr alone in assessing renal function in the 8 
week AD as it reflects urea levels more precisely.[192] A further more accurate 
way of evaluating GFR would be to calculate Cr clearance on paired urine Cr and 
plasma Cr from metabolic cages. Unfortunately the resources for accurate 
metabolic cage collection of urine in mice were not available. 
2.4.4  Concluding Remarks 
Despite the limitations of the murine AD CKD model these experiments suggest 
that circulating sGal-3 levels are increased in CKD with an increased monocyte 
and renal tissue Gal-3 expression compared to controls. This interesting 
observation is further explained in the next chapter.   
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Chapter 3: The Adenine diet induced uraemic phenotype in Gal-3 -/- mice. 
3.1  Background. 
3.1.1 Gal-3 and Monocyte/Macrophage tissue infiltration in fibrotic disease 
WT plasma Gal-3 and circulating monocyte Gal-3 are elevated in mice fed an AD 
(Chapter 2, section 2.3.2.1, 2.3.3.1) and kidneys from WT AD fed mice 
demonstrate macrophage accumulation (Chapter 2, give heading). Furthermore 
leucocyte-endothelial attachment and transmigration is abrogated in 
experimental inflammation in Gal-3 -/- mice (heading ref). However the main 
leucocyte studied in a model of bacterial infection (Streptococcus pneumoniae) 
was neutrophil-endothelial interactions and transmigration.[94, 95] There is 
evidence that shows that elevated monocyte expression of Gal-3 could facilitate 
monocyte-endothelial adhesion and transmigration.[96, 200] In vitro data suggest 
monocyte migration is driven by soluble or immobilised Gal-3 in a dose 
dependant manner and that monocyte migration is driven by interactions with 
ECM proteins laminin and fibronectin.[200] Migratory interactions between 
monocyte Gal-3 and ECM proteins are via the CRD.[200] The same study also 
documented macrophage migration in response to Gal-3. 
Macrophage organ infiltration and M2 differentiation propagate fibrotic 
disease.[92] Whilst there is theoretical in vitro data available to hypothesize that a 
reduction in macrophage accumulation in fibrotic models on Gal-3-/- , there is no 
in vivo data to support it.[56, 60, 120, 121] Gal-3 -/- mice do have an ameliorated 
fibrotic disease phenotype compared to WT controls in a model of renal 
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fibrosis.[60, 121] A hypothesis to be tested on Gal-3 -/- mice is that they may have 
an ameliorated disease phenotype after being fed an AD due to reduced 
monocyte transmigration, renal infiltration and renal macrophage accumulation.  
3.3.2  M2 macrophage differentiation promoted by Gal-3. 
A secondary hypothesis would be that of the effect of absence of Gal-3 on 
monocyte and macrophage differentiation phenotype. M1 classical 
differentiation of macrophages occurs in the initial inflammatory cascade and is 
promoted by Th1 cytokines (IFN-γ and IL-12).[90, 91] M2 ‘alternative’ macrophage 
differentiation predominates, and is implicated in, chronic fibrotic disease.[77] M2 
differentiation of macrophages can be induced by Th2 cytokines (IL-4 and IL-3) 
and M2 differentiated macrophages display characteristic markers including 
Ym1/CHI313 and Fizz1/Retnla.[92, 93, 201-203] In vitro Gal-3-/- murine macrophages 
show classical activation on stimulation with LPS but do not demonstrate M2 
markers (CHI313 and Retnla) upon stimulation with Th2 cytokines IL-4 and IL-
13.[77] In vivo m stimulation of macrophages with Th2 cytokines induces secretion 
of Retnla and CHI313.[204-208]  
3.3.3  Monocyte Phenotypic change in CKD 
There are conflicting data about the relative importance of Ly6Chigh and Ly6Clow 
monocyte populations in fibrosis and a recent discovery of a Ly6Cint group in a 
model of uraemia.[209, 210] Monocyte phenotype in fibrotic disease has been 
studied using a bleomycin model of pulmonary fibrosis. Monocytes and 
macrophages are not involved in the initial inflammatory phase but during the 
pro-fibrotic phase monocyte phenotype and alternative macrophage 
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differentiation are important determinants of progression.[210] Depletion of 
circulating monocytes reduced the numbers of tissue resident macrophages at 
24 h and reduced the markers of alternative macrophage activation.[210] Ly6Chigh 
monocytes exacerbated lung fibrosis and promoted an increase in CHI313 
positive (alternatively activated) macrophages.[210] In a murine model of AKI 
(bilateral renal pedicule clamping) tissue infiltrated and resident CD11B+Ly6Chigh 
cells predominated during the initial inflammatory phase, a CD11B+Ly6Cint group 
during the initial resolving period and Ly6Clow during the fibrotic phase of renal 
recovery.[209] Markers of ‘alternative macrophage’ activation were increased 
with the expression of CD11B+Ly6Clow cells. This paper did not look at circulating 
monocyte phenotype, only the tissue resident CD11B cell populations. In the AD 
model of progressive renal fibrosis both Ly6C and Ly6G (granulocyte) +ve cells 
were elevated compared to those fed SD, again this did not look at circulating 
monocyte populations.[211] This chapter presents data on the AD uraemic 
phenotype in Gal-3-/- mice looking at renal macrophage numbers within the 
kidney, circulating monocyte phenotype and macrophage differentiation 
markers. 
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3.2  Methods. 
3.2.1  Generation of Gal-3 -/- mice 
Jackson Laboratories create Gal-3-/- mice using the following methodology: For 
the Lgals3 targeted mutation allele; a targeting vector containing neomycin 
resistance and herpes simplex virus thymidine kinase genes was used to disrupt 
3.7kb of sequence that includes exons 2, 3 and 4. The construct was 
electroporated into 129/Sv and C57BL/6 and SJL derived WW6 embryonic stem 
(ES) cells. Correctly targeted ES cells were injected into outbred MF-1 
blastocysts. The resulting chimeric male animals were crossed to 129 female 
mice. Heterozygotes were crossed to generate homozygotes. The single targeted 
mutation lines were subsequently crossed to generate a double mutant. The 
double mutant strain was then backcrossed to C57BL/6 for 5 generations prior to 
arrival at The Jackson Laboratory. WT mice used were 6 week old male C57BL/6 
mice purchased from Charles River. Animals of the two strains were age-
matched but were not littermates. Gal-3-/- mice used in experiments were 
genotyped on a randomised basis (section 2.2.4.9) to confirm absence of the Gal-
3 gene. 
3.2.2  Genotyping Gal-3 -/- mice 
3.2.2.1  Gal-3 -/- genotyping: DNA extraction 
Mouse kidneys from WT and Gal-3-/- mice were taken from -80oC storage. DNA 
was extracted by proteinase K digestion buffer (DB). 2 mm samples of kidney 
tissue were placed in microcentrifuge tubes with 500 µl of DB. The tubes were 
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incubated at 55oC with gentle mixing overnight. The proteinase K was denatured 
by 10 min incubation at 94oC and samples centrifuged at 16,000 g for 15 min.  
3.2.2.2  Gal-3 -/- genotyping: Polymerase chain reaction 
A standard polymerase chain reaction was carried out in a 50 µl reaction mixture 
containing 2 µl cDNA. Buffer and Taq Polymerase were purchased from Life 
Technologies, Paisley, U.K. Briefly, a mastermix containing buffer, dNTP mix, 
MgCl2 and dH2O and Gal-3 primers were added. A second mastermix containing 
Buffer, Taq Polymerase and dH2O was prepared and added to individual cDNA 
samples. Finally the two mastermixes for each sample were combined. PCR was 
performed using the G-Storm model GS1 machine, (KAPA Biosystems, Somerton 
Biotechnology Centre, U.K.). 
3.2.2.3  Gal-3 -/- genotyping: Gel analysis of amplified samples 
20 µl of PCR products were mixed with Gel Loading Buffer (Sigma Cat no: G2526) 
and separated on a 2% agarose gel, which was then stained with Gel Red 
(Cambridge Biotechnology, Cat. no: BT41003) for 30 min before photographing 
over UV light (UVIP) [Fig 14]. 
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Figure 14: Agarose gel of amplified cDNA products from WT and Gal-3 -/- kidneys. 
Double Gal-3-/-Mutant=~150 base pairs (bp), Heterozygote = ~150 bp and ~220 
bp, Wild type=~220 bp. This gel confirms all samples from purchased Gal-3-/- 
mice are true knockouts. 
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3.2.3 qPCR – markers of fibrosis and M2 macrophage differentiation. 
Methodology for conducting qPCR is covered in detail in Chapter 2 (section 
2.2.5). Samples were analysed by comparative quantitation using a WT SD fed 
animal kidney as a calibrator gene as a comparator. All qPCR used reverse 
transcriptase controls and no-template controls. Samples were performed in 
triplicates and where the replicative take off standard deviation between the 
triplicate values exceeded 0.6 the sample was not used for analysis.  All genes of 
interest had their comparative concentration divided by a housekeeper gene 
(18s) to correct for varying amounts of RNA. Gel electrophoresis of DNA was not 
undertaken for CD68, CHI313 and Retnla genes because of time constraints.  
3.2.4  FACS analysis of Monocyte Phenotype 
Methodology for FACS analysis of circulating monocytes is covered in detail in 
Chapter 2 (section 2.2.6). 
3.2.5  Histology: Haematoxylin and Eosin Staining (H+E) 
Histology was only performed on tissues from experiment and control mice in 
the AD model.  Mice received a terminal anaesthetic with intra-peritoneal X/K, 
following cardiac aspiration of blood, a loin incision was performed, the left 
kidney was identified, dissected free of perinephric fat and briefly washed in 
0.9% saline, then placed in 10% Formalin for 48 h. After 48 h the samples were 
placed in 70% ethanol for storage. Subsequent steps in histological processing 
for H+E staining, picosirius red staining and immunohistochemistry were 
undertaken by the William Harvey Institute, Bart’s Cancer Pathology Services. 
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Samples were embedded in paraffin and cut to 4µm thick sections. Kidney 
sections were deparaffinised and stained with Gill’s II Haematoxylin.  
 
3.2.5.1  Histological assessment of Renal Tubulointerstitial Nephritis 
damage. 
All scoring was performed by myself blinded to diet treatment and to the 
genotype of mouse (WT or Gal-3 -/-) and then validated by a Consultant 
Histopathologist, similarly blinded. Histological scoring methods were also 
discussed and agreed for describing tubulointerstitial damage, collagen scoring 
(picosirius red) and interstitial macrophage infiltration (F4/80 
immunohistochemistry). Digital images of mounted kidney specimens were 
acquired using a Hamamatsu nanozoomer (Hamamatsu Phototics Hertfordshire, 
U.K.). Mounted digital images of kidney sections were acquired using NDPview2 
software (Hamamatsu Photonics K.K. Cat no: U12388-01).  6 x40 were taken of 
each animal’s renal cortex and medulla using NDPview2 software (Hamamatsu 
Photonics K.K. Cat no: U12388-01) [Fig 5]. Each image was assessed for the % of 
slide area with histologically ‘normal’ interstitium using ImageJ™ software. 
Histologically normal interstitium was easily distinguished from damaged 
interstitium by the presence of ‘back to back’ tubules, intact tubular lumen 
epithelium, non-dilated tubular lumen and lack of infiltrating cells. The AD 
creates ‘islands’ of preserved renal interstitium amongst severe tubulointerstitial 
damage which could be mapped out and area assessed by ImageJ™ software [Fig 
15-17].  The primary focus of assessing damage was to define the extent of 
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tubulointerstitial damage rather than glomerular abnormalities. Glomeruli were 
subtracted from the total slide area being assessed to ensure the overall area 
assessed represented tubulointerstitium only. Each animal therefore had 6 
measurements for % ‘histologically normal’ area in the cortex and 6 
measurements for medulla. These were then averaged to give a mean % 
histologically normal cortex and medulla per animal.  
 
 
 
Figure 15: H+E Renal tubular interstitial damage scoring methodology 1, original 
image x40 magnification. This image has been digitally generated from a slide 
using NDPview2 software. The image is representative of renal cortex from a WT 
AD fed mouse. Areas of preserved tubulointerstitium are clearly visible enabling 
subsequent mapping and area assessment with ImageJ software™. Each animal 
had 6 images from cortex and 6 images from medulla. 
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Figure 16: H+E Renal tubular interstitial damage scoring methodology 2, screen 
shot of H+E tubulointerstitial damage area scoring using Image J™ software. 
Glomeruli are identified (yellow line) and glomerular area within the yellow 
demarcation is measured to subtract from final area to be assessed. There are 2 
glomeruli in this view which have to be measured separately. 
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Figure 17: H+E Renal tubular interstitial damage scoring methodology 3, screen 
shot of H+E tubulointerstitial damage area scoring using ImageJ ™software. The 
area of ‘normal’ interstitial appearance is mapped (yellow line) and measured, 
then subtracted from the total slide area (minus glomerular area) and expressed 
as a percentage. The final % represents the % area with tubulointerstitial 
damage. Each mouse had 6 measurement from cortex and 6 from medulla. The 
mean of the 6 % values was generated to give a mean cortical and mean 
medullary value per mouse. The mean cortical and medullary values were 
combined to give an overall tubulointerstitial damage % per animal.  
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3.2.6 Collagen quantification by Picosirius Red stain. 
The following method was used by the institute of Cancer pathology services to 
perform Picosirius red staining of collagen from murine kidney samples. Kidney 
specimens from WT and Gal-3 -/- mice fed AD or SD were embedded in paraffin 
and cut to 4µm thick sections. The paraffin samples were de-waxed and 
hydrated. Hydrated specimens were then placed in picosirius red for 1 h. The 
samples were then sequentially washed in 2 changes of acidified water. The 
sample was dried by blotting then dehydrated in 3 changes of 100% ethanol 
before being cleared with xylene and mounted in a resinous medium. Digital 
images were acquired using a Hamamatsu nanozoomer (Hamamatsu Phototics). 
x40 slide images were then taken using NDPview2 software (Hamamatsu 
Photonics). 
3.2.6.1  Morphometric histopathological collagen scoring using Sirius 
red. 
Morphometric analysis was used to assess collagen content of harvested kidneys 
fed SD or AD at 3 weeks. The scoring methodology was discussed and agreed by 
Professor Mike Sheaff, a Consultant Histopathologist. Collagen staining of kidney 
specimens using picosirius red staining and image J software has been verified 
and published before.[212, 213]  As mentioned earlier the assessors, both myself 
and Professor Sheaff, were blinded to the genotype of the mouse, WT or Gal-3 -/-
, and the treatment received AD or SD. Scoring was done for all specimens and 
random samples verified by Professor Sheaff. The x40 digital slide of picosirius 
red stained cortex or medulla was analysed using ImageJ™ software. The x40 
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image can be split into red, blue and green channels. The green filter is selected 
and red threshold is manually adjusted until intracellular contents are not 
present leaving extracellular collagen staining only. The area measured therefore 
reflects the collagen area. Because the images often had significant and variable 
tubular lumen sizes the actual area of tubulointerstitium was also measured by 
manual thresholding. The result was a value of measured area ascribed to 
extracellular collagen staining and a measured area of tubulointerstitium. The 
value of this was expressed as a percentage for each of the 6 cortical, 6 
medullary images per animal.  
 
Figure 18: Histopathological renal collagen quantification methodology 1.Screen 
shot of original x40 image uploaded onto ImageJ™ analysis. This is a 
representative image of the cortex of a WT mouse fed AD and harvested at 3 
weeks. The picosirius stain gives collagen (found extracellularly) a red colour and 
stains low collagen containing tissues yellow. ImageJ™ can filter this image into 
green, red and blue channels. For assessing red staining the green channel is 
subsequently selected. 
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Figure 19: Histopathological renal collagen quantification methodology 2. Screen 
shot of original image split into a green channel 
 
Figure 20: Histopathological renal collagen quantification methodology 3. Screen 
shot of automated threshold for red before manual adjustment. 
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Figure 21: Histopathological renal collagen quantification methodology 4. Screen 
shot of red threshold manually adjusted to exclude nuclear staining. The area of 
red staining was quantified per slide and the mean % area of 6 cortical and 6 
medullary slides per animal recorded. 
 
3.2.7 Statistical Analysis 
Demographic data with a ‘normal’ or Gaussian distribution is described using 
mean and standard deviation (SD) values. All data described by mean and SD 
values have been tested for the presence of a Gaussian distribution using the 
‘D’Agostino and Pearson omnibus normality test’ on GraphPad Prism™ software. 
Where data did not have a Gaussian distribution it is described by median and 
interquartile range values. Tests of variance between normally distributed data 
in matched groups was by a 2-tailed unpaired t-test using a p value of <0.05 to 
infer a significant difference between groups. Where data did not have a 
Gaussian distribution a Mann-Whitney test was used to test the significance of 
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differences between the 2 groups median values and range, again a p-value of 
<0.05 is ascribed to be significant.  
3.3 Results. 
3.3.1   Reduction in weight loss in AD fed Gal-3 -/- mice compared to WT 
AD fed mice. 
10 week old male WT and Gal-3 -/- mice were allocated into cages receiving 
either SD or AD over 3 weeks. Body weight data from the first experiment is 
shown in Figure 22 and subsequent data for further Gal-3 -/- mice used is shown 
in Figure 23 (a+b). Each week body weight was measured for all individuals per 
cage. WT and Gal-3 -/- mice receiving AD and SD had equivalent body weighs at 
the start of the diet [Fig 22, 23]. After 3 weeks WT AD fed mice had a significantly 
lower mean body weight than AD fed Gal-3 -/- mice with no significant difference 
between either genotype fed SD [Fig 22]. This discrepancy was apparent on 
visual inspection of the animals [Fig 22].  Percentage body weight loss over the 3 
weeks diet was calculated by dividing the mean weight of the animals in a cage 
after 3 weeks with the weight at the start of the diet. The mean % weight loss 
was 39.89% in WT AD fed mice and 29.44% in Gal-3 -/- AD fed mice [Fig. 22c]. 
There was no % weight loss in SD fed mice of either genotype. The mean amount 
of diet consumed per cage did not differ significantly between the 2 AD fed 
groups over the 3 weeks [Fig. 23d]. 
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3.3.2   Lower median plasma Cr in Gal-3 -/- mice fed AD after 3 weeks 
compared to WT mice. 
Plasma Cr was measured at 3 weeks of AD or SD in WT and Gal-3 -/- mice. The 
experiment demonstrated an overall significantly lower Cr in Gal-3 -/- AD fed 
mice compared to WT AD fed mice [Fig 24]. It was clear that the Gal-3-/- mice did 
not have absolute protection but partial given they still had an elevated median 
Cr compared to both SD groups [Fig 24]. None of the data passed the normality 
test individually or combined. Mann Whitney was therefore used as a non-
parametric test of difference between WT AD and Gal-3 -/- mice.  
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Figure 22: Body weight differences between WT and Gal-3 -/- mice fed AD or SD 
(a) Photographic images of representative anaesthetised WT and Gal-3 -/- mice 
after 3 weeks AD or SD. WT AD fed mice were noticeably smaller and on 
laparotomy had subjectively less adipose tissue than the matched Gal-3 -/- AD fed 
mice. (b) Body weights from 10 week old WT and Gal-3 -/- mice fed SD or AD for 3 
weeks. Values displayed are mean weight (SD) in grams. WT AD mice had lower 
body weights than the Gal-3 -/- AD fed mice from 1 week post diet initiation but 
this was not significant until 3 weeks. Body weight WT AD vs Gal-3 -/- AD weight = 
16.78 g (±0.41) vs 23.1 g (±1.61) p= 0.0043 (Mann Whitney). 
  
147 
 
 
Figure 23: Body weight and diet consumed over 3 weeks of AD or SD in 10 week 
old WT and Gal-3 -/- mice. (a) Scatter plot of individual results for body weight at 
Week 0 at the start of the AD with error bars showing mean body weight and 
standard deviation values. There were no significant differences between 
animals at Week 0. (b) At week 3 all mice in WT and Gal-3 -/- groups fed AD have 
lost weight with lower body weights in the WT AD fed group. (c)  % weight lost is 
greater in WT AD fed mice compared to Gal-3 -/- AD fed mice, there was no 
weight loss in either SD fed group at 3 weeks. (d) Scatter plot of diet consumed 
over the 3 week period. Each value represents 1 cage within the group with a 
calculation of diet weight consumed per mouse per day over the week. 
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Figure 24: Plasma Cr in WT vs Gal-3 -/- mice fed AD in 3 repeated experiments. (a) 
Scatter graph of individual Cr values with the error bar showing median and 
interquartile range values (b) Summary table of plasma Cr from 10 week old WT 
and Gal-3 -/- mice at 3 weeks fed AD or SD. Cr values shown are median (SD). The 
data demonstrates a significantly lower median plasma Cr in Gal-3 -/- AD fed 
mice, 45.26 µmol/L (±16.92) vs WT AD  54.27 µmol/L (±16.93) p=0.0317 (Mann-
Whitney).  
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3.3.3   Reduction in kidney tissue area affected by tubulointerstitial 
injury in Gal-3 -/- mice fed AD compared to WT mice 
After 3 weeks AD or SD WT and Gal-3 -/- mice were harvested and kidneys were 
processed for H+E staining to assess the extent of tubulointerstitial injury. On 
macroscopic inspection the kidneys of both AD fed genotypes were smaller than 
the SD fed mice [Fig 25]. There was little difference in visual inspection between 
Gal-3 -/- and WT AD fed kidneys. Both were smaller than the SD kidneys. The dry 
weight of the kidneys was also equivalent between both AD fed genotypes [Fig 
25b]. The renal cortex and medulla from each kidney was examined separately 
for each kidney. SD fed WT and Gal-3-/- mice had normal appearances of the 
interstitium with little cell infiltrate, preserved tubule epithelial cell size, 
structure with little intraluminal debris. Both AD fed genotypes had severe 
tubulointerstitial injury with intra-luminal debris, disruption of tubular 
architecture, an increased interstitial cell infiltrate and dilated tubular lumens. 
The damaged area was darker stained and easily identifiable at low power (x20) 
and high power (x40) light microscopic examination [Fig 26 +27]. Gal-3-/- AD fed 
mice had more identifiable ‘islands’ of preserved tubulointerstitium than WT AD 
fed mice. This was more apparent in the renal cortex than the medulla [Fig 28]. 
Glomeruli were not histologically formally assessed as the AD injury is primarily a 
tubulointerstitial injury. Formal measurement of tubulointerstitial damage was 
undertaken at X40 magnification by measuring the % of the image area that had 
evidence of tubulointerstitial damage. WT AD fed mice had significantly more % 
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area of tubulointerstitial damage than the Gal-3-/- AD fed mice in both cortex and 
medulla [Fig 29]. 
 
Figure 25: Photograph and dry weight of kidneys from AD and SD fed WT and 
Gal-3-/- mice at 3 weeks of diet. (a) Photographic image of representative 
harvested whole kidneys from WT and Gal-3 -/- mice fed AD or SD for 3 weeks. It 
can be seen that although WT and Gal-3-/- kidneys are smaller than the 
equivalent SD fed mice, there is little macroscopic difference between the 2 AD 
fed mouse genotypes. (b) Equivalent kidney dry weight between WT and Gal-3 -/- 
AD fed mice at 3 weeks.  
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Figure 26: Representative image of x10 magnification renal cortex from AD fed 
WT and Gal-3 -/- mice. The highlighted area within a black line is preserved 
undamaged renal tubulointerstitium. The darker area with dilated tubular 
lumens is tubulointerstitial damage. Gal-3-/- had more areas of preserved 
‘normal’ tubulointerstitium than WT AD fed mice which was formally assessed 
and quantified [Fig 29]. 
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Figure 27: Representative x40 slide images of renal medullary tissue of WT and 
Gal-3 -/- mice fed SD or AD after 3 weeks. Scale bars = 100µm. Both images of SD 
fed mice show preserved architecture with back to back tubules, limited tubular 
lumen space and no inflammatory cell infiltrate. In contrast both AD groups 
show dilated tubular lumen with intra-luminal debris and inflammatory cell 
infiltrate. 
 
153 
 
 
Figure 28: Histological quantification of renal tubular interstitial damage (a) 
Results from histological assessment of the % area of tubulointerstitial damage 
on kidney H+E slides. Values scored for each group refer to mean (SD) % values 
in each group. The p-value refers to WT AD vs Gal-3-/- AD comparison only, p 
value =0.0357 in cortex, medulla and combined comparisons respectively (Mann 
Whitney). (b) Scatter graph of % values with mean (SD) bar. AD fed animals only 
are displayed no SD data is displayed on the scatter graph. 
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3.3.4  Similar collagen staining in WT and Gal-3 -/- mice.  
Collagen staining by morphometric analysis of picosirius red staining was 
undertaken on 10 week old WT fed SD (n=2), WT fed AD (n=6), Gal-3 -/- fed SD 
(n=2) and Gal-3 -/- fed AD (n=5). Kidneys were harvested after 3 weeks diet. Both 
AD fed genotypes had significantly more % area stained red in cortical, medullary 
and overall indicating more collagen deposition [Fig 29]. There were no 
significant differences in % area stained red between the WT AD fed mice and 
Gal-3-/- mice fed AD [Table 23].  
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Figure 29: Representative x40 images of picosirius red staining from medullary 
samples in all genotype and diet groups at 3 weeks. These light microscopy 
images show a significant collagen deposition (red areas) in both AD fed groups. 
Collagen laydown has occurred extracellularly particularly around connective 
tissue. There were no obvious differences in collagen laydown between the WT 
and Gal-3 -/- AD fed mice. Picosirius stains non-collagen containing tissues yellow 
and gives a red appearance to nuclei. Distance marker = 100µm. 
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Table 23: Quantification of collagen staining from renal cortex and medulla in 
WT and Gal-3-/- mice fed AD or SD at 3 weeks. % collagen staining by picosirius 
red of kidney cortical, medullary and overall kidney tissue. Each mouse was fed 
AD or SD for 3 weeks then harvested. Kidneys were processed for histology and 
stained with picosirius red. 6 x40 images of cortex and 6 of medulla were taken 
per animal. Photometric analysis using ImageJ™ software allowed assessment of 
the collagen staining per image. After 6 measurements were taken the mean % 
was used per cortex, per medulla and combined. There were no significant 
differences between AD fed WT or Gal-3-/- mice. Data shown as median 
(standard deviation). 
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3.3.4.1  No significant difference in markers of fibrosis on qPCR 
Murine kidneys from 10 week old WT and Gal-3 -/- mice fed SD or AD for 3 weeks 
were harvested and processed for qPCR.  Comparative quantification analysis 
using a WT SD fed animal as the calibrator gene demonstrated significantly 
elevated procollagen (1), TGF-β and α-SMA in the WT AD fed animals compared 
to WT SD fed animals in both their respective genotypes. When comparing WT 
AD fed mice with Gal-3-/- AD fed mice there were no significant differences. 
There was a non-significant increase in procollagen (1) and α-SMA in the WT 
compared to Gal-3 -/- AD fed group and a non-significant increase in TGF-β in the 
Gal-3-/- AD group [Fig. 30]. Interestingly the Gal-3-/- SD fed animals had lower 
median gene expression than WT SD fed animals for all 3 markers of fibrosis. This 
did not reach significance for α-SMA and procollagen (1). Mann Whitney test of 
significance was not able to applied to the TGF-β PCR because the use of a WT 
SD fed animal as the calibrator gene meant that there were repeated values of 1.  
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Figure 30: qPCR of fibrosis markers from kidney homogenate from 10 week old 
WT and Gal-3 -/- mice fed SD or AD. Analysis was by comparative quantitation 
using SD fed WT mice as the calibrator gene and 18s as a housekeeper gene. Bar 
charts show median (range) of relative gene expression of (a) procollagen (1), (b) 
α-SMA and (c) TGF-β. (d) Table of relative gene expressions showing median 
(standard deviation). All the markers of fibrosis had an increase in relative gene 
expression in AD fed animals but there were no significant differences between 
WT or Gal-3-/- mice fed an AD. Gal-3-/- SD fed mice had a non-significant tendency 
for a lower relative gene expression in all 3 genes. 
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3.3.5   Macrophage numbers are equivalent between WT and Gal-3 -/- 
AD fed mice at 3 weeks. 
AD fed animals had more F4/80 +ve cells and CD68 gene expression than SD fed 
animals in both the respective genotypes. After 3 weeks diet the mice were 
harvested and kidneys processed for immunohistochemistry using an F4/80 
primary antibody and conjugated HRP secondary antibody for 
immunoperoxidase staining. This resulted in 2 WT SD kidneys, 3 WT AD kidneys, 
3 Gal-3 -/- SD kidneys and 5 Gal-3 -/- AD fed kidneys being available for histological 
analysis. The cortex only was examined due to limitations set out in Chapter 2 
(2.2.7.2). F4/80+ve cells were identified predominantly amongst areas of 
tubulointerstitial injury in the AD fed mice of both genotypes [Fig 31]. There 
were more than double the mean amount of F4/80 +ve cells in AD fed mice than 
SD fed mice, WT SD vs WT AD= 35.84 cells/slide (±2.34) vs 110.6 (±22.18) and 
Gal-3 -/- SD vs Gal-3 -/- AD= 23.09 (±12.42) vs 116 (±17.84) [Fig. 32]. Whilst the AD 
mice had a large increase in macrophage numbers within their renal cortex 
compared to SD fed mice, there were no significant differences between WT AD 
and Gal-3-/- AD fed mice. WT SD and Gal-3 -/- SD fed mice appeared to have 
equivalent numbers of F4/80 +ve cells but with the small numbers available it 
was not possible to assess for significant differences [Fig 33].  
qPCR data obtained from studying CD68 gene expression supports the 
immunohistochemistry F4/80 staining findings. CD68 gene expression is 
increased in AD fed mice regardless of genotype compared to their respective SD 
fed groups [Fig 33]. There is a non-significant increase in CD68 gene expression in 
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WT AD fed mice compared to Gal-3 -/- AD fed mice, relative to the WT SD CD68 
gene expression (calibrator gene) WT AD vs Gal-3 -/- AD = 2.25 (±0.66) vs 1.35 
(±0.77). The result is non-significant on Mann-Whitney testing [Fig 33]. 
 
 
 
Figure 31: x40 representative images of kidney cortex with primary anti- F4/80 
macrophage antibody and secondary conjugated HRP immunoperoxidase stain. 
Distance marker represents 100µm. F4/80 positive cells are localised to areas of 
tubulointerstitial damage. Due to limited histological data it was not possible to 
discriminate between tissue resident macrophages and infiltrating macrophages. 
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Figure 32: Relative renal cortical macrophage numbers by histological 
quantification. (a) bar chart of median (range) numbers of F4-80 +ve cells per x40 
image. (b) Statistics of the number of F4-80+ve cells per x40 image. Median value 
obtained is derived from 6 x40 images per animal. Total numbers of animals 
analysed were too small to have confidence in normality of distribution. There 
were no significant difference between WT AD fed mice and Gal-3-/- mice. All AD 
fed mice had an increase in numbers of F4/80 positive cells suggesting 
macrophage accumulation within renal cortex.  
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3.3.5.2  Equivalent renal CD-68 gene expression between WT and Gal-3 -
/- AD fed mice. 
 
 
Figure 33: Relative CD68 gene expression by comparative quantitation using a 
WT SD fed mouse as a calibrator gene and 18s as a housekeeper gene. Bar chart 
shows median (range) and table shows median (standard deviation). The WT AD 
fed group had significantly more CD68 gene expression, WT SD vs WT AD, p= 
0.0067.  There was a non-significant increase between Gal-3 -/- SD and Gal-3 -/- 
AD fed animals, p= 0.08 (Mann Whitney). There was no significant difference 
between WT AD fed mice and Gal-3 -/- AD fed mice CD68 expression. 
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3.3.6  Circulating monocyte subset change towards a Ly6Clow phenotype in WT 
mice fed AD. 
The Ly6C subset changes in experimental uraemia were examined in WT mice 
before including Gal-3-/- mice. There were 2 WT control groups used to compare 
data with a WT 3 Wk. AD fed mouse experiment group. The first control group 
were WT mice fed SD. The second control group were WT mice fed AD for 1 
week. Data had previously shown 1 Wk. AD fed mice had equivalent plasma Cr, 
body weight and sGal-3 to SD fed mice (Chapter 2). The 1 Wk. AD fed mouse 
group was included to investigate if there were effects mediated by the AD 
independent of uraemia. In statistical analysis the control groups were combined 
to enable significance testing between control animals and 3 Wk. AD fed mice. 
The mice in all groups were harvested at the same time and circulating whole 
blood analysed for Gal-3 and Ly6C fluorescence according to methodology 
outlined in Chapter 2 (section 2.2.6.1). Monocytes were identified using FlowJo™ 
software using size/granularity characteristics and positivity for Ly6C [Fig 34 
a+b]. The Ly6C fluorescence sorting revealed 3 distinct groups a large group with 
low Ly6C fluorescence similar to isotype fluorescence therefore considered Ly6C 
negative and not monocytes. The 2 remaining cell populations were split into 
Ly6Clow and Ly6Chigh groups. These Ly6Chigh and Ly6Clow groups could be readily 
identified for each animal and relative proportions as well as Ly6C MFI could be 
analysed [Fig. 34c]. There was no clear identification of a separate Ly6Cint group 
that could be isolated and measured. Ly6Cint were almost certainly present but 
not readily discernible. The results showed a significant reduction in the overall 
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Ly6C MFI of all gated monocytes from control groups (SD and 1 Wk. AD) 
compared to the 3 weeks AD fed mice [Table 24]. When the individual Ly6C 
subsets were gated and analysed it was shown that there was a sequential 
significant reduction in the proportion of cells gated as Ly6chigh and an increase in 
the proportion gated as Ly6Clow between control mice and 3 Wk. AD fed mice 
[Fig 35, Table 24]. There was a reduction in fluorescence intensity of Ly6c MFI 
within both Ly6Chigh and Ly6Clow gated groups in 3 Wk. AD fed mice that reached 
significance [Table 24]. Both Ly6Chigh and Ly6Clow monocyte populations have an 
increase in their Gal-3 expression at 3 weeks AD compared to (SD and 1 Wk. AD) 
controls [Table 24]. 
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Figure 34: FACS analysis of murine whole blood, gating for monocytes (a) 
monocyte population identified by size and granularity (SSC/FSC) is selected 
from flow cytometry data using FlowJo™ software. (b) The population selected in 
(a) has Ly6C fluorescence measured (log scale) and uses an isotype control (not 
shown) to select out all events (cells) that are Ly6c +ve. (c) Ly6c +ve cells form 2 
distinct groups reflecting Ly6C high and Ly6C low monocytes. These can be selected 
to measure Ly6C MFI and Gal-3 MFI using a Gal-3 fluorochrome. All cell 
populations were automatically selected in the same way. 
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Table 24: Gal-3 and Ly6C measurement of gated monocytes by FACS in WT mice 
fed SD, AD for 1 week and AD for 3 weeks. 
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Figure 35: Ly6C high and low monocyte subsets in WT mice fed SD, AD for 1 week 
and AD for 3 weeks. Representative measurements of Ly6c fluorescence 
intensity on the X axis and cell count on the Y axis. The numbers of monocytes 
increase overall from (a) WT SD fed mice, (b) WT mice fed Ad for 1 week and (c) 
WT mice fed AD for 3 weeks. As the animals become more uraemic during the 
time given an AD the relative proportion of Ly6C high monocyte subset falls and 
the Ly6C low group increases. There is likely to be a group of Ly6Cint monocytes 
formed but the data was unable to separate a distinct grouping. Ly6Cint 
monocytes have previously been designated pro-inflammatory.  
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3.3.7  Gal-3-/- circulating monocytes resist AD uraemic phenotypic change 
towards a Ly6Clow phenotype. 
FACS was performed on whole blood from 10 week old animals fed AD or SD for 
3 weeks. After processing blood for FACS there were 2 WT SD animals, 5 WT AD, 
3 Gal-3 -/- SD, and 5 Gal-3 -/- AD fed animals available for analysis. Live cells were 
gated by SSC/FSC characteristics and from this gate monocytes were gated by 
double positive staining for CD11B and Ly6C compared to an isotype control [Fig. 
36]. There was a monocytosis observed once more for animals fed AD but with 
equivalent results between both AD fed groups [Table 25]. WT SD vs WT AD 
median % double positive events out of all gated events = 7.12 (±0.56) vs 25.26 
(±8.15), Gal-3-/- SD vs Gal-3 -/- AD = 11.45 (±3.53) vs 27.42 (±6.6). In SD fed groups 
the Gal-3 -/- mice had a higher median % of gated monocytes falling within the 
Ly6Chigh group and lower median % falling within the Ly6Clow group [Table 25, Fig 
37]. Because of small numbers in the WT SD group it was not possible to test 
statistical significance. However, there was a non-significant reduction in the 
proportion of gated monocytes falling within the Ly6CHigh monocyte subset and 
corresponding non-significant increase in the Ly6Clow group in WT AD fed mice 
compared to Gal-3 -/- mice fed AD [Table 25, Fig 38]. Given the reduction in size 
of the Ly6Chigh subset and increase in Ly6clow subset it could be expected that 
there would be a greater reduction in overall Ly6C MFI in WT mice fed AD. In fact 
WT AD fed mice had a significantly higher Ly6C MFI than Gal-3 -/- AD fed mice 
[Table 26]. The overall monocyte and Ly6Clow Ly6C MFI were both significantly 
higher for Gal-3-/- mice fed AD compared to WT AD fed mice. The WT mice had 
169 
 
more Ly6Clow monocytes expressing higher Ly6C than the Gal-3-/- AD fed mice. 
The probability is that the WT mice had developed a sizeable Ly6Cint population 
and the Gal-3-/- mice did not. The Gal-3-/- mice just developed a Ly6Clow 
monocyte population with low levels of expressed Ly6C. However no discrete 
Ly6Cint group could be identified from gating for analysis.  
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Figure 36: Gating monocytes by SSC/FSC and CD11B/Ly6C staining 
characteristics. Representative scatter graphs of gating techniques using 
FlowJo™ software. (a) Live cells including monocytes are gated using size and 
granularity (FSC/SSC) characteristics. (b) The selected events (cells) have their 
CD11B and Ly6c fluorescence measured and compared to an isotype control for 
both Ly6C and CD11B. (C) Representative CD11B and Ly6C fluorescence intensity 
scatter plot with double positive gate shown. All samples automatically had the 
same gating applied to them. 
  
171 
 
 
 
Table 25: Relative proportions of monocytes falling into Ly6Chigh and Ly6Clow 
groups between treatment and genotype groups. Values shown are for 
monocytes defined as for cells gated for positivity to both CD 11b and Ly6C. WT 
and Gal-3 -/- mice fed AD develop a monocytosis shown here by elevated double 
positive CD 11b and Ly6c. There are no significant differences between the 2 AD 
fed genotypes in the % of events being gated. The WT AD fed group had a 
significantly increased Ly6c expression (MFI) compared to Gal-3 -/- AD fed mice, 
167 (±17.85) vs 129.4 (±21.11) p = 0.0317 (Mann-Whitney). Although the Ly6C 
MFI does significantly increase overall in double positive cells in WT AD fed mice 
compared to Gal-3 -/- this is not a uniform increase, with a reduction of both 
numbers and Ly6c intensity in the Ly6Chigh group in the WT AD compared to Gal-
3 -/- AD. The Ly6Clow group is the beneficiary with a non-significant increase in 
numbers and significant increase in MFI, 147.8 (± 22.88) vs 105.7 (±25.07) p= 
0.0241 (Student t-test). 
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Figure 37: Representative individual mouse blood samples showing Ly6C 
fluorescence staining patterns of double positive (CD11B/Ly6C +ve) events. The 
data show an increase in overall double positive (monocyte numbers) in AD fed 
mice of both genotypes. There is an increase in the Ly6Clow (FL1-H-) monocyte 
population and reduction in the relative proportion of the Ly6Chigh (FL1-H+) 
population in WT AD mice compared to WT SD fed mice. This increase is less in 
Gal-3-/- AD fed mice. 
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3.3.8  Gal-3-/- kidneys subject to AD have reduced CHI313 expression 
compared to WT AD fed mice.  
Gene expression of M2 macrophage activation was assessed by qPCR. The 
kidneys from mice fed SD or AD for 3 weeks were processed for qPCR looking at 
CHI313 and Retnla gene expression and analysed by comparative quantitation 
using a WT SD kidney as a calibrator gene. There were 3 animals in each study 
group (WT SD, WT AD, Gal-3-/- SD and Gal-3 -/- AD) that had sufficient nucleic acid 
purity for further analysis by qPCR. CHI313 demonstrated an increase in both AD 
fed groups compared to their respective SD fed genotype. There was a much 
larger increase in relative gene expression in the WT AD groups compared to the 
Gal-3-/- group. However the variance in WT AD CHI3L3 increase (122, 45 and 20 
fold) meant that there was no significance to the obvious comparison with Gal-3 
-/- AD fed animal CHI313 increase (6.37, 3.83 and 1.91 fold) [Fig. 38 b+c]. Retnla 
gene expression demonstrated a reduction compared to the WT SD comparator 
in all the remaining study groups [Fig. 39 a+c]. WT AD fed animals had a greater 
median reduction in Retnla expression than Gal-3 -/- AD fed mice (0.14 (±0.07) vs 
0.65 (±0.28)). However this was not found to be statistically significant.  
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Figure 38: Markers of macrophage M2 differentiation from kidney homogenates 
after 3 weeks of AD or SD. Results show comparative quantitation analysis using 
a WT SD fed mouse as the calibrator gene and 18s as a housekeeper gene. Bar 
charts show the median (range) of comparative quantitation of gene expression 
using a WT SD fed animal as the calibrator gene and table gives Median 
(standard deviation) of values. (a+c) Retnla expression is reduced in WT AD and 
Gal-3 -/- SD and AD fed animals. (b+d) CHI313 is elevated in both AD fed groups 
but markedly in the WT AD fed group (relative gene expression values of 122, 45 
and 20. The spread of data and the low numbers of animals studied meant that 
the increase was not significant on Mann Whitney analysis when compared to 
Gal-3 -/- animals fed AD (relative expression values of 6.37, 3.83 and 1.91).  
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3.4 Discussion 
3.4.1  Gal-3 -/- mice have an ameliorated disease phenotype when given an AD 
despite evidence of equivalent amounts of fibrosis and macrophage 
accumulation. 
Gal-3 -/- mice suffer significantly less weight loss and have higher plasma Cr at 3 
weeks AD compared to WT controls. The variability in baseline plasma Cr values 
between in WT SD fed mice may reflect the variability of the Cr assay used. 
Because of the amount of plasma being used for analysis for a Gal-3 ELISA an ‘in-
house’ Cr assay was used which required a lower volume of plasma (25 μl) 
compared to the external laboratory normally used by our laboratory (100 μl). 
The co-efficient of variation on samples assayed ‘in-house’ was performed 
(which were conducted in duplicate where volumes were sufficient (see Chapter 
2 section 2.7.1 Table A1). WT SD and Gal-3 -/- SD plasma Cr values were higher 
than expected in group 3 compared to group 1. I would suggest this may be 
because of user variation in performing the 2 step assay or because of 
degradation of the assay. Although used within the expiry date the standard 
used to measure Cr against demonstrated a CV of 13.39 which suggests 
difference in the measured Cr standard value between assays.  
3.4.2  Gal-3 -/- offers partial not absolute protection from the AD. 
Gal-3 -/- AD fed mice had a partial protection as they had significantly lower 
creatinine than the WT controls. It is even more relevant that weight loss in Gal-
3 -/- mice was significantly less which would lead to higher Cr levels than the low 
176 
 
muscle mass from WT AD fed animals. The fact that Gal-3-/- mice do get a CKD 
with the AD is reflective of the real in-vivo effect of a knockout model in the 
complex multifactorial process of nephrolithiasis induced interstitial fibrosis. The 
Gal-3-/- mice did consume an equivalent amount of diet. They did get equivalent 
crystal deposition in their tubules; the difference is in the subsequent 
inflammation.  As described in the introduction Gal-3 is not required for any 
absolute function in an animal. To see real differences between WT and Gal-3 -/- 
animals in this model large numbers of animals are required. The effect of 
absence of Gal-3 is clearly not absolute since Gal-3 -/- mice still get renal fibrosis, 
weight loss and elevated plasma Cr. The feasibility of maintaining large colonies 
of Gal-3 -/- mice is difficult and subject to time and financial restraints.  
3.4.3  Equivalent markers of fibrosis and collagen laydown between 
genotypes. 
Renal histological assessment of the extent of tubulointerstitial damage suggests 
that Gal-3-/- mice have significant reduction in both cortical and medullary 
damage. However histological assessment of collagen deposition and qPCR 
markers of fibrosis are equivalent between WT and Gal-3-/- mice fed AD.  At 
baseline the SD fed Gal-3 -/- mice have lower markers of fibrosis than WT SD fed 
mice. Both procollagen (1) and α-SMA are non-significantly elevated in WT AD 
fed mice compared to Gal-3-/- mice fed AD. The duration of the diet of 3 weeks 
may be too short to observe what amounts to a chronic disease process 
(fibrosis). Similar gene markers of fibrosis and collagen deposition in Henderson 
et al. work investigating an UUO model of renal fibrosis took 7 days to establish 
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significant differences between the genotypes.[60] The same model took 14 days 
to establish significant differences in procollagen (1) in the Okamura et al. 
paper.[121] Unlike Henderson et al. study (8)the Okamura paper found an increase 
in picosirius red staining at 14 days post UUO in the Gal-3-/- mice. TGF-β is non-
significantly elevated in Gal-3-/- mice fed AD at 3 weeks. Because the PCR data 
comes from homogenised kidneys the cell type of origin cannot be determined. 
The UUO model observed a similar TGF-β gene expression between the 
genotypes at 14 days post-operation.[60]  
3.4.2  AD induces WT circulating monocyte Ly6C subset change. 
WT mice fed an AD have a reduced Ly6Chigh population and an increased Ly6Clow 
population. No discrete Ly6Cint formation was found but it doesn’t rule out the 
possible formation of this group. The increase in Ly6C number could arise from 
newly derived monocytes from bone marrow after initiation from the diet. There 
presumably must be an expansion from the bone marrow given the significantly 
increased numbers of monocytes at 3 weeks of AD. The increase could also come 
from circulating Ly6Chigh monocytes differentiating into Ly6Clow monocytes. 
Whether renal tissue monocytes levels (transmigrated monocytes) are also 
Ly6clow monocyte predominant remains to be examined. Previous work does 
suggest an increase in renal transmigrated Ly6Clow monocytes in the AD.[211]  
3.4.3 Gal-3 -/- mice avoid Ly6c monocyte subset change. 
Gal-3 -/- SD fed mice have a lower Ly6c MFI at baseline than WT SD fed mice. The 
functional significance of this is not known. Gal-3 -/- mice fed AD for 3 weeks had 
a non-significantly reduced Ly6CLow proportional increase. Again for describing 
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differences in an ‘optimising’ molecule as opposed to an absolute molecule 
numbers may have to be increased to demonstrate statistical difference. 
However regardless of the cause or effect of Ly6C monocyte fluorescence, it is 
different between WT and Gal-3-/- mice fed SD or AD. It is tempting to 
hypothesize the formation of a distinct Ly6Cint group as demonstrated in uraemia 
with a human comparison.[209] However, in the work presented here no distinct 
subset using CD11B and Ly6c markers could be demonstrated. Further analysis 
using additional monocyte subset markers may be helpful in discriminating a 
distinct group.  
3.4.4  Reduced CHI313 and elevated Retnla in Gal-3-/- fed AD compared to WT 
AD fed mice 
CHI313 and Retnla are markers of alternative activation of macrophages. CHI313 
was elevated in both AD fed genotypes compared to SD fed mice. It cannot be 
certain what the source of the CHI313 is because lymphocytes (B and T-cells), 
monocytes and dendritic cells also secrete these proteins in a Th2 cytokine 
environment.[203] The predominant infiltrating cell type observed in the AD is 
F4/80 +ve cells (cells of macrophage/monocyte lineage). Given the evidence that 
CHI313 is very highly expressed by alternatively activated macrophages It can be 
hypothesized that a reduction in CHI313 gene expression reflects a reduction in 
renal macrophage expression.[203] It may be the renal macrophage population in 
the Gal-3 -/- mice fed AD have a reduced M2 differentiation. Further work 
identifying the Th1 and Th2 cytokine profile from homogenised kidneys as well 
as evaluation of further markers of M1 and M2 differentiation would help 
examine this hypothesis. There is a precedent for strongly positive CHI313 
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expression and downregulated Retnla below control levels in 2 models of chronic 
fibrotic disease predominated by alternatively activated macrophages 
(experimental acinomycetoma by Nocardia brasilienis,  chronic musculoskeletal 
inflammation by alphavirus and acute Trypanosoma cruzi infection of the 
heart).[214-216] In these experiments, despite a Th2 cytokine rich environment and 
elevated CHI313 expression suggesting M2 macrophage differentiation, the 
Retnla levels were low and lower than the control mice indicating active 
downregulation. Retnla is a negative feedback mechanism for IL-13. It could be 
downregulation of Retnla is a mechanism to maintain chronically elevated IL-13 
and persistence of the Th2 environment.  
3.4.4  Concluding Remarks 
Gal-3-/- mice have partial protection from the AD phenotype with less renal injury 
which is independent of collagen deposition, markers of fibrosis and macrophage 
accumulation. Gal-3-/- circulating monocytes have a non-significant reduction in 
the WT AD phenotypic change towards a Ly6Clow population. That Gal-3-/- 
monocytes have a significantly lower overall Ly6C MFI despite fewer monocytes 
falling within the Ly6Clow class points to the emergence of a Ly6Cint group in WT 
mice that is not reflected in Gal-3-/- animals. Renal macrophage markers of 
alternative differentiation are reduced in Gal-3 -/- kidneys fed an AD. Therefore 
observed partial protection in Gal-3-/- mice fed AD is mediated via differences in 
inflammation rather than fibrosis. 
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Chapter 4: The influence of Gal-3 on leucocyte-endothelial interactions in 
extra-renal microvasculature. 
4.1  Background 
We have already determined that, whilst monocyte Gal-3 is elevated, there is 
not a significant difference in number of macrophages in renal cortex between 
Gal-3 -/- mice fed an AD and WT mice fed an AD (Chapter 3). The conclusion from 
this observation is that differences in the AD injury to WT and Gal-3-/- mice are 
independent of the numbers of monocytes transmigrating from blood to renal 
tissue and subsequent differentiation into macrophages. There were no 
differences between the AD fed genotypes used, however, both AD fed WT and 
Gal-3-/- mice did demonstrate significantly increased macrophage infiltration and 
a circulating monocytosis compared to SD fed mice.   
The argument for elevated Gal-3 resulting in increased adhesion and leucocyte-
endothelial (LEC) rolling is still compelling from earlier published data on Gal-
3.[47, 56, 94, 95, 200] Vascular beds cannot be thought of as one and it may be that the 
intra-renal microvasculature during significant adenine induced inflammation 
behaves differently from other tissue microcirculation. We cannot assume that 
monocyte LEC are equivalent to neutrophil LEC in the AD. Leucocytes of 
monocyte and macrophage cell lineage are the predominant cell in the later 
fibrotic stages of the AD model.[170] The initial inflammatory response is 
characterised by neutrophil infiltration.[211] Gal-3 promotes adhesion of human 
neutrophils to endothelial cell monolayers, laminin and fibronectin in vitro.[217] 
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Gal-3 significantly increases the number of neutrophils, monocytes and 
eosinophils recruited to murine air pouches.[58] Neutrophil granulocytes do 
accumulate within the kidney during the AD as demonstrated by Hochst et al. by 
Ly6G (granulocyte specific) renal staining.[211]  We sought to define neutrophil 
Gal-3 expression and LEC interactions in vivo during the AD in an extra-renal 
tissue microcirculation, the cremasteric microcirculation. 
4.1.1  Intravital Microscopy 
IVM has been used to describe the effects of Gal-1 on LEC but there is no 
published data exists using Gal-3-/- mice.[218] IVM is defined as the observation of 
a system in a living organism by microscopy. It is a useful tool to analyse and 
dissect complex biological and disease mechanisms in vivo including leucocyte 
recruitment and the adhesion cascade. IVM can measure each step in this 
cascade of leucocyte rolling, flux, rolling velocity, adhesion and emigration.[219] 
Small animals are frequently used, especially mice, due to the ability to use 
genetic manipulations. Transilluminating light microscopy can visualise 
vasculature and leucocytes within thin and translucent tissues (such as 
cremaster muscle and peritoneal membrane) without the need for contrast 
enhancing methods.  
 
The microcirculation of more solid tissue can be studied using contrast enhanced 
epifluorescence microscopy.[220] IVM and epifluorescent microscopy enables the 
use of dye to identify cell populations and measure vascular permeability. 
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Intravenous injection of FITC-labelled Bovine Serum Albumin (BSA) allows the 
evaluation of vascular albumin leakage as a marker of vascular permeability.[221] 
Leucocytes can be labelled with dyes (rhodamine) to facilitate visualisation in 
thicker or opacified tissues.[222]Leucocytes can also be labelled with 
fluorochrome-conjugated antibodies to distinguish leucocyte subpopulations. 
[220] When performing IVM, inflammogens (LPS, PAF) can be added to buffer 
(perfusing the vasculature) or given intravenously to stimulate leucocyte 
recruitment so basal and inflamed measurements can be determined. Antibodies 
to selectins and other adhesion molecules can be given intravenously to block 
their effects and determine their influence on the visualised adhesion cascade. 
An ischaemia reperfusion model can be induced by cross clamping the superior 
cremasteric muscle temporarily occluding the primary artery and vein.  
 
There are technical criticisms of IVM; it is an intricate microsurgical technique. 
To create suitable optical conditions necessitate surgery to the cremaster. The 
localised trauma of surgery can act as a local and even systemic inflammatory 
stimulus so microdissection techniques have to be optimised to minimise such 
trauma. Exposing the cremaster can cause drying which leads to microvascular 
dysfunction so the muscle must be continuously perfused with bicarbonate 
buffered saline with controlled temperature and ph. The technique is performed 
under anaesthesia. Anaesthetics can have effects on the macro and 
microcirculation. Additionally there are potentially confounding issues that may 
contribute to local cremasteric inflammation in a chronic uraemic animal that 
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could be falsely ascribed to uraemic effects. These uraemic effects include 
platelet dysfunction increasing the bleeding time during surgery and hence 
increasing the pro-inflammatory effect on LEC with local extravasation. Specific 
to the AD model mice are frequently half to a third the weight of their sham 
littermates and their testicular weights are just under half that of the shams. The 
cremaster appears smaller and surgical margins are closer to the viewed blood 
vessels potentially causing a local inflammatory stimulus and making surgery 
more intricate than that in larger animals.  
4.2 Methods 
4.2.1  IVM 
IVM of the cremaster of 10 week old WT and Gal-3-/- fed SD or AD was 
performed as described by Gavins and Giddens et al.[223, 224] Once anaesthetised, 
the mouse is placed ventral side up onto a viewing stage. The right testicle 
covered by cremasteric muscle is exposed having blunt dissected overlying skin 
and fascia. Tissues are regularly perfused with bicarbonate buffered saline at 
370C to prevent the tissues drying out which can elicit an inflammatory response 
manifest as increased leucocyte rolling. The cremasteric sack is immobilised and 
carefully opened by thermal cautery along the ventral axis and the use of 
microscissors. Once opened, the testicle is moved away and the cremaster held 
open for microscopic viewing with 4 hooks. The cremaster is transilluminated 
with a 12-V 100 W light source. Tissues are superfused with thermostated (370C) 
bicarbonate buffered saline. The cremaster is placed on a Plexiglas stage and 
mounted on a Zeiss Axioskope with a water immersion objective lens 
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(magnification x40) and an eyepiece (x10 magnification) [Fig 40]. Post-capillary 
venules can be identified from morphology and the presence of rolling 
leucocytes. For each animal a total of 3-5 post capillary venules should be 
viewed. The diameter of the venules should be between 25-50 µm. The 
microscope is fitted with a red blood cell optical velocimeter which measures red 
blood cell centreline velocity. Mean red cell velocity can then be worked out by 
the formula Vmean = centreline velocity/1.6. This enables the Wall Shear Rate 
(WSR) to be calculated by the formula WSR = 8000 x (Vmean/diameter). Post 
capillary venules are recorded and timed for off-line analysis. The parameters 
scored then include cell flux (number of leucocytes passing a fixed point/ min), 
rolling velocity (time for a leucocyte to travel 100 µm), number of adherent cells 
(stationary leucocyte on endothelium for > 30 s) and number of emigrated cells 
in tissue outside the vessel in a 100 x 50µm area [Fig 39].   
186 
 
 
Figure 39: IVM Measurements made during off-line analysis of murine 
cremasteric post capillary venules. Adapted from Gavins et al, Journal of 
Pharmacological and Toxicological Methods 49 (2004) 1–14.[223] 
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Figure 40: IVM laboratory equipment set up. A mouse with cremaster exposed is 
placed on a Plexiglas slide. Buffer is heated with a water bath and dripped onto 
the cremaster whilst a x40 image is recorded for off-line analysis later. During 
the procedure post capillary venules can be identified with optimum dimensions 
for analysis. 3-5 vessels are recorded per mouse. Adapted from Lim et al.[225] 
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4.2.2 Flow Cytometry 
Flow cytometry of whole blood was performed as described in Chapter 3 
(section 2.2.6.1). Gating of neutrophils is described in the results (4.3.1.).  
4.3  Results 
4.3.1 Permeabilized neutrophil Gal-3 levels are elevated after 3 weeks AD. 
12 x 10 week old WT mice were used to analyse circulating neutrophil Gal-3 
levels by flow cytometry. 5 mice were placed on SD for 3 weeks, 5 mice were 
given 1 week of AD and 5 mice given 3 weeks of AD. Only 2 of the SD fed mice 
had suitable processing for FACS analysis. For statistical analysis the SD fed mice 
and 1 Wk. AD group were considered the controls. As described before the 1 Wk. 
AD mice were found to have no difference in plasma Cr, weight or sGal-3. The 
use of the 1 Wk. AD mice was to look for direct effects of AD independent of the 
development of Uraemia. For statistical comparison the SD and 1 Wk. group 
were pooled together.  All mice were harvested on the same day for flow 
cytometry. Permeabilized neutrophils were gated from live events by size and 
granularity characteristics (SSC/FSC) into a live cell gate. They were subsequently 
identified by SSC characteristics and negativity to Ly6c [Fig 41]. No neutrophil 
specific antibody was used, this was because 2 fluorochromes were already 
being used to analyse Ly6c and Gal-3. There was a sequential increase in Gal-3 
MFI from SD fed mice (Median Gal-3 MFI = to 1 Week AD to 3 weeks AD. This 
was statistically significant using a Kruskall-Wallis test of the variance of the 
median values between the 3 groups (p= 0.0158). The low number of animals in 
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the WT SD group meant Mann-Whitney analysis was not able to be performed 
between the WTSD and WT AD 3 week groups. There was a significant increase 
in Gal-3 MFI between WT AD 1 week and WT AD 3 week groups,                        
Gal-3 MFI = 288 (±67.17) vs 664 (±113), p= 0.0079 (Mann-Whitney) [Fig 42]. 
 
 
Figure 41: Selecting granulocyte populations using FACS gating. (a) Granulocytes 
were gated by selecting a group representing live cells. (b) Granulocytes were 
then selected by their ssc characteristics and negativity for Ly6c. Within this gate 
measurements of Gal-3 MFI were taken. All samples had the same gating 
automatically applied to them. 
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Figure 42: Measured granulocyte Gal-3 expression by FACS. Measured 
permeablised granulocyte Gal-3 MFI in 3 week AD group is significantly higher 
than that found in WT fed a SD and WT given AD for 1 week murine granulocytes 
(Kruskall-Wallis, p= 0.0158). 
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4.3.2  LEC adherence but not transmigration is increased in WT AD fed mice 
The IVM experiments were not performed contemporaneously. Approximately 
2-3 IVM preparations could be performed in a day. The subsequent availability of 
Gal-3 -/- mice meant that the IVM experiments were performed a year apart. The 
first experiments used WT mice only and the second experiments used both 
genotypes. Out of a total of 30 WT mice there were only 6 WT SD fed mice and 5 
WT AD fed mice that had adequate preparations for video analysis post 
procedure [Fig 44]. Out of 15 Gal-3-/- mice only 8 were suitable (3 SD and 5 AD 
fed). Therefore out of 45 mice only 11 (42.2%) had adequate preparations, 
though the success rate was lower in the WT AD fed groups (WT AD = 27.7%). 
Mean blood vessel diameter was acceptable for all groups apart from the WT SD 
fed mice. Optimal post capillary vessel diameter is 25-50μm [Table 26]. The 
mean WT SD fed mouse vessel diameter was 64μm (±0.46). This resulted in a 
non-significantly lower mean RBC velocity and wall shear stress [Table 26]. The 
WT AD and both Gal-3 -/- groups had similar RBC velocity and wall shear stress 
parameters. The median number of leucocytes adherent to endothelium for > 30 
s was significantly elevated in WT AD fed mice compared to WT SD fed mice and 
both Gal-3 -/- groups (Krushkall-Wallis, p=0.0115. WT AD vs Gal-3 -/- AD, 9.75 cells 
(±1.36) vs 3.13 cells (±3.13), p=0.0079 (Mann–Whitney) [Table 26]. Median 
leucocyte rolling velocity (the time taken for a leucocyte to roll along 100 μm of 
endothelium expressed as μm/s) was non-significantly reduced in WT AD 
compared to WT SD mice, p= 0.426 (Mann Whitney). The median rolling velocity 
for both Gal-3-/- groups was significantly lower than the WT SD fed mouse 
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(p=0.0456, Krushkall Wallis). The reduced rolling velocity was non-significantly 
reduced between WT AD and Gal-3-/- AD fed groups [Table 26].  There were no 
significant differences in numbers of transmigrated cells between the 
experiment groups [Table 26].  
 
Figure 43: Representative image of IVM VHS video recording performed by 
author of thesis. Striated cremasteric muscle can be seen either side of a post 
capillary venule. Leucocytes can be visualised as circular bodies rolling along the 
endothelium. The dark circular black marks are to measure RBC velocity. 
Measurements can be drawn onto the television screen to demonstrate distance 
markers of 50 μm to 100μm in order to measure velocity, adhesion and 
transmigration. 
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Table 26: Intravital microscopy results from all treatment and genotype 
groupings. The technically challenging element of microsurgery in the 
cremasteric preparation for IVM meant low success rates especially in AD fed 
mice. Body weights of WT AD and Gal-3-/- mice were significantly lower than Gal-
3-/-AD fed mice and the SD fed mice. This was a confounding factor to the 
experiment. Leucocyte adherence to post-capillary venule endothelium was 
significantly elevated in WT AD fed mice compared to Gal-3 -/- AD fed mice 9.75 
cells (±1.36) vs 3.13 cells (±2.47), p=0.0079 (Mann Whitney). Despite this, there 
was not an increase in numbers of transmigrated leucocytes into cremasteric 
tissue. Leucocyte rolling velocity appeared to be slower in Gal-3-/- SD and AD fed 
mice though this did not reach significance. 
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4.4  Discussion 
4.4.1  Elevated neutrophil Gal-3 in the AD.  
Granulocytes were selected based on size, granularity and negativity to Ly6C 
(defined by an isotype control) only. There was no cell-specific stain used. A 
distinct cell group could be identified with granularity and negativity to Ly6C. It is 
feasible, without using a neutrophil specific marker that other cell types could be 
included in the analysis. Elevated granulocyte Gal-3 could have a number of 
repercussions on neutrophil behaviour in the AD. Feasibly the elevated Gal-3 
could increase adhesion to post-capillary venule endothelium and ECM proteins 
leading to the increased adherence demonstrated by IVM. Gal-3 induces 
oxidative burst in neutrophils, increases Il-8 production, L-selectin- shedding and 
it protects neutrophils from apoptosis.  
4.4.2  Leucocyte-endothelial adhesion is increased in WT AD fed mice 
compared to      Gal-3-/- AD fed mice but weight loss is a significant confounding 
factor.  
As described in Chapter 2, WT AD fed mice have a significant weight loss over the 
3 weeks of treatment. Their mean testicular weight was lower (data not shown). 
The smaller testicle size meant that the available surface to perform 
microsurgery was reduced. The technique was intricate and the number of 
animals with adequate preparation were low with only 5 WT AD fed mice out of 
18 (28%) attempted resulting in acceptable cremasteric preparations. Whilst 
leucocyte adherence appeared to be significantly increased, the lack of elevated 
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transmigration may point to the adhesion originating from inflammation that 
occurred during surgery as opposed to that induced by systemic uraemia. To 
reduce the impact of surgery a rest period was observed for all animals after 
exposing the cremaster of 30 min to allow the post-surgical inflammation to 
resolve. There remains a concern that with a smaller surgical area; the 
probability is that some WT AD leucocyte adherence reflected surgery and not 
the underlying model. The cremaster also appeared more opaque in the Gal-3-/- 
mice, probably reflecting fat content, this made video analysis more difficult.  
4.4.3  Lack of cell specific staining 
The IVM performed by myself was pure light microscopy with no cell specific 
staining. It would be interesting to see if the leucocyte adherence represented 
granulocytes or monocytes. As already discussed there is a monocytosis 
associated with the AD. The monocytes also reduce their Ly6C expression 
towards a Ly6Clow phenotype. This Ly6Clow phenotype has also been observed to 
have ‘patrolling’ characteristics of rolling along post capillary endothelium. 
Another hypothesis would be that the leucocytes observed are neutrophils. The 
finding of an increase in leucocyte-endothelial adherence is interesting with the 
above caveats. The use of flow chambers could be a useful in vitro method of 
validating this finding.  
4.4.4  Reduced rolling velocity in Gal-3-/- SD and AD fed mice 
The findings presented here of an elevated sGal-3 and increased monocyte and 
granulocyte Gal-3 in the AD led to the hypothesis that rolling velocity would be 
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higher in Gal-3-/- mice. In fact, they were significantly lower compared to WT SD 
fed mice but not significantly changed from the WT AD fed mice. The IVM data 
for the WT SD fed mice does have to be viewed with some caution. The post-
capillary venules in this group were larger than ideal, RBC velocity and wall shear 
stress were non-significantly reduced compared to all other groups.  
4.4.5 Concluding Remarks 
Despite limitations of this technique, one can suggest that Gal-3 is not associated 
with transmigration of leucocytes in the uremic milieu. Observed differences 
between WT and Gal-3 AD fed mice are not related to quantitative changes in 
numbers of leucocytes infiltrating inflamed tissue. This finding at a 
microcirculatory level is further validated by our data showing equivalent 
number of leucocytes of monocyte/macrophage lineage within the renal tissue 
and peritoneal in AD fed mice of both genotypes (Chapter 2.3.5).   
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Chapter 5 Discussion and future work 
5.1 Discussion 
5.1.1 Elevated sGal-3 in the AD 
This thesis has described an elevated sGal-3 in the AD model of uraemia and 
tubulointerstitial fibrosis. A hypothesis could be that the origin of increased sGal-
3 is secreted and derived from the increased circulating monocyte Gal-3 
measured by FACS analysis. Most epithelial surfaces can express Gal-3 and the 
author did not measure endothelial expression of Gal-3 or urinary Gal-3. Gal-3 is 
filtered by the glomerulus so plasma levels could increase with reducing GFR. As 
discussed before measurement of urinary Gal-3 would be difficult to distinguish 
between filtered and collecting duct tubular epithelial Gal-3 which is present in 
the urine. To measure precise glomerular filtration of Gal-3 would require 
injection of a known amount of labelled sGal-3 and measured in the urine over a 
given time frame to determine renal clearance. Intravenous injection of sGal-3 is 
difficult and has not been used often as it acts as a red call agglutinin. The level 
of sGal-3 in the AD at 3 weeks is equivalent to levels seen in human disease.  
5.1.2 Solid organ Gal-3 is elevated predominantly in the kidney during the 
AD.  
 sGal-3 is elevated at week 3 of the AD and all organs will be perfused with blood 
containing this increase. The solid organs (lung, heart, aorta) do not show 
differences between the AD and SD fed mice. The kidney does demonstrate 
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increased Gal-3 expression from intrinsic epithelial expression and from 
infiltrating cells into the interstitium.  The AD model is not long enough to 
demonstrate some aspects of uraemia elevated (e.g. elevated PTH). The link 
between reduced GFR, elevated sGal-3 and the uremic cardiac fibrosis and 
remodelling requires more examination. Gal-3 is implicated in cardiac fibrosis 
and vascular fibrosis which form part of the phenotype of human CKD.[226, 227]  
Preferably an animal model that is longer in duration and causes hypertension 
with uraemia may allow further examination of the role Gal-3 may have in 
uremic cardiovascular disease. The 5/6 th Nx model is a chronic uremic model 
with hypertension and would suit. Unfortunately we were not able to reliably 
demonstrate uraemia in this model. A potential hypothesis linking CKD Gal-3 and 
cardiac fibrosis is the monocyte. Cardiac remodelling is driven by interactions 
between monocyte/macrophage and fibroblast.[228] We have demonstrated AD 
induced elevated monocyte Gal-3 and differential monocyte phenotype towards 
a Ly6clow group in WT AD fed mice. This Ly6Clow group gives rise to M2 activated 
macrophages and correlates with fibrotic disease.[92] In my hypothesis CKD 
induces elevated monocyte Gal-3 and Ly6clow differentiation. In the presence of 
hypertensive myocardial stress uraemia induced Ly6clow monocytes could 
infiltrate myocardial tissue, differentiate into M2 activated macrophages and 
induce myocardial fibrosis.  
  
200 
 
5.1.3 Phenotypic differences in response to AD between WT and Gal-3-/- mice 
are independent of markers of fibrosis and monocyte/macrophage numbers. 
Gal-3 has been described as an optimising molecule. Not necessary for any 
absolute function but required for optimal function. To see significant difference 
in ‘optimal’ as opposed to absolute function numbers have to be high. There was 
no doubt that Gal-3 -/- mice received a significant uraemia and interstitial fibrosis. 
The limitation of using a knockout model was the need to limit numbers to those 
essential in order to be efficient and not waste animals. The AD model had a high 
mortality so was optimised to use for 3 weeks rather than 4. This was to 
maximise efficiency and reduce costing whilst still being able to see differences 
between the genotypes. Increasing the numbers of animals may have led to a 
significant difference in markers of fibrosis given there was a non-significant 
reduction in collagen staining, Procollagen (1) and α-SMA in Gal-3-/- mice fed AD 
compared to WT. Renal monocyte /macrophage numbers were equivalent 
between WT and Gal-3-/- fed AD but there was a striking difference in markers of 
M2 macrophage activation with very high levels of CHI313 expressed. Because 
renal interstitial macrophages were not isolated for qPCR, rather the whole 
kidney, the source of CHI313 cannot be described as wholly macrophage 
derived. Dual staining on immunohistochemistry for CHI313 and CD-68 would 
enable co-localisation of the CHI313 to be confident of its derivation. A 
hypothesis could be that observed partial protection in the AD phenotype in Gal-
3-/- mice (less weight loss and lower creatinine) is due to differences in the local 
inflammatory environment produced by an M2 predominant versus M1 
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macrophage phenotype. To further assess this hypothesis the kidneys from WT 
AD fed mice and Gal-3-/- AD fed mice could be homogenised and M1 and M2 
cytokine content assessed over time. A further piece of work to describe the 
cause of differences would be to study the differences in granulocyte number 
and function over time. As previously described neutrophil function is affected 
by Gal-3 expression. WT AD fed mice had elevated granulocyte Gal-3 content by 
FACS compared to WT SD fed mice. Whilst the chronic fibrotic phase of the AD is 
mediated by macrophages the initial inflammatory cascade is mediated in part 
by granulocytes.  
5.1.4 Monocyte Gal-3 as a therapeutic target 
Gal-3 has useful functions that have been demonstrated in human studies. sGal-
3 has an inverse relationship to glycated haemoglobin levels in diabetics and is 
negatively correlated to obesity.[50] The role of Gal-3 as an AGE and ALE receptor 
able to safely remove AGE is one that could be physiologically  useful in 
conditions like diabetes and CKD associated with elevated AGE and ALE levels. 
Gal-3 is part of the normal inflammatory response and resolution. In CKD the 
results in this thesis would suggest that there is an inappropriate increase in Gal-
3 which correlates with monocyte phenotype change and chronic renal fibrosis 
in a time dependent fashion during the AD. A complete therapeutic blockage of 
Gal-3 may have deleterious effects of an individual to mount an appropriate 
inflammatory response or to handle AGE and ALE accumulation in disease. A 
more focused therapeutic targeting of monocyte Gal-3 may have benefits in 
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reducing fibrosis but preserve other useful components of Gal-3 e.g. neutrophil 
Gal-3 response to infection. 
5.2  Future work 
5.2.1  Gal-3 -/- chimera 
There is a monocytosis affected by the AD in both WT and Gal-3-/- mice. It is not 
known whether the monocyte subset change occurs in newly derived monocytes 
from bone marrow or whether they are pre-existing circulating monocytes. The 
creation of a chimera WT mouse with Gal-3-/- myeloid cells and Gal-3 -/- with WT 
bone marrow would enable the discovery of whether it is the myeloid local 
environment that induces monocyte Ly6C change or the circulating plasma 
environment.  
5.2.2 In vitro signalling and fibroblast work 
Dissecting the intracellular signalling pathways of Gal-3 in cells of the 
monocyte/macrophage lineage could enable further understanding of why this 
galectin is elevated in CKD. It is feasible that the initial inflammatory phase of the 
AD may have different pathways triggering an appropriate Gal-3 response and 
then an inappropriate elevated Gal-3 expression occurs subsequently through a 
different pathway. Cell signalling pathways would have to be reviewed at 
different times during the AD in vivo.  
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5.2.3 Measurement of Gal-3-/- monocyte ly6C phenotype exposed to 
recombinant Gal-3 
Could Gal-3-/- monocytes exposed to recombinant Gal-3 exhibit similar Ly6C 
changes in the AD as WT monocytes? The answer to this would inform about 
whether the Gal-3 monocyte subset difference is inherent, at the level of 
myeloid development or whether it is the local circulating environment that 
contributes to Ly6C subset change. This would enable targeted therapy towards 
myeloid development or towards the current situation of intravenous Gal-3 
antagonism.    
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Figure A1: Myocardial Gal-3 expression by immunohistochemistry. Gal-3 positive 
cells (arrows) in WT myocardial section at x40 magnification and bar chart of 
number of Gal-3 positive cells per x40 section (6 section per animals) n= 3 in 
each group. No significant differences between the SD fed mice, median number 
of Gal-3 +ve cells per x40 slide = 2.17 (±0.93) vs 3.5 (±1.4) p. = 0.4 (Mann 
Whitney). 
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Table A1 : Inter and Intra assay Coefficient of variation for the Quantichrom™ Cr 
assay.The intra-assay CV has a mean CV of 14 duplicates within the same assay 
and gives the SD in brackets. The Inter-assay CV has the overall CV for 5 different 
Cr assays hence does not have a SD. 
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Table A2: Intra-assay Coefficient of Variation for commercial Gal-3 ELISA 
performed on plasma and tissue samples.  
Subsequent to these data – any sample with a Co-efficient of Variation greater 
than 20% was excluded from analysis. 
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Table A3: Interassay coefficient of variation using Gal-3 Standards results from 5 
different ELISA’s on mouse plasma samples. 
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Table A4: Elevated plasma Gal-3 on centrifugation of mouse whole blood > 800 g 
in the process of separating plasma. 
 
 
  
 
Plasma Gal-3 (ng/ml) at 0 weeks AD + SD 
 
Centrifuge >800 g 
 
Centrifuge <800 g 
19.845 4.02 
26.985 10.89 
34.46 6.4 
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